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Renal proximal tubular epithelial cells perform a wide variety of kidney-specific 
functions. Due to their function in glomerular filtrate concentration and drug transport, 
they are a major target of drug-induced toxicity and hence important for in vitro 
nephrotoxicology. However, respective approved in vitro models based on renal cells 
have not been developed yet. One major obstacle is cellular de-differentiation of human 
primary renal proximal tubular cells (HPTC), which are most interesting for such 
applications, under in vitro conditions. HPTC are also important for the development of 
bioartificial kidneys (BAKs) and also in this application cell performance is of critical 
importance.  
 
In order to establish a reliable source and to characterize cell performance, I established 
in the laboratory a protocol for isolating HPTC from human kidney samples. The freshly 
isolated HPTC were characterized using qPCR, immunostaining, immunoblotting and 
functional assays. In addition, I characterized commercial HPTC. The results showed that 
both freshly isolated and commercial HPTC displayed many characteristics of HPTC, but 
showed some changes in gene expression patterns and expressed some markers specific 
for other parts of the nephron.  
 
I also established a co-culture system between HPTC and human primary endothelial 
cells. The results showed that HPTC stimulated endothelial cells to secrete a mixture of 
growth factors, which in turn improved HPTC performance. HPTC showed improved 
proliferation, marker gene expression and enzyme activity in co-cultures. Also, the long-
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term maintenance of epithelia formed by HPTC was improved. In order to determine 
which growth factors were responsible for these effects, qPCR analysis was performed. 
The results pointed to a central role of transforming growth factor-β1 (TGF-β1) and its 
antagonist alpha-2-macroglobulin (A2M). The impact of these factors on HPTC was 
further confirmed by additional experimental approaches involving supplementation with 
recombinant growth factors. Overall, the results showed that HPTC induced endothelial 
cells to secrete increased amounts of specific growth factors, which balanced each other 
functionally and improved cell performance. Together, the results revealed that co-culture 
systems are useful for analyzing the cross-talk between these cell types which plays an 
important role in renal disease and repair. Furthermore, the characterization of defined 
microenvironments, which positively affect HPTC, is helpful for improving the 
performance of this cell type in in vitro applications. 
 
The central role of TGF-β1 and its antagonists in regulating HPTC performance was 
further confirmed by our findings that treatment with bone morphogenetic protein-7 
(BMP-7), which is a TGF-β1 antagonist, improved maintenance of epithelia formed by 
HPTC for extended time periods. In addition, the functional performance of the HPTC 
was improved. The effects of BMP-7 were strongly concentration-dependent. Following 
these findings, I generated BMP-7-expressing HPTC by genetic engineering for the 
development of BMP-7-producing bioartificial kidneys. The hypothesis underlying this 
work was that HPTC-produced BMP-7 would improve cell performance in the device by 
autocrine/paracrine signaling. Furthermore, pre-clinical studies revealed beneficial effects 
of BMP-7 on kidney recovery and hence there is a substantial interest in using BMP-7 for 
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the treatment of kidney disease. Apart from the improvement of cellular functions, a 
BMP-7-producing BAK would allow the delivery of the growth factor to kidney patients. 
My results showed that HPTC-produced BMP-7 was bioactive and improved HPTC 
performance through autocrine signaling. In addition, our results suggested that the 
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1.1 Structure and function of renal proximal tubular cells 
The functional unit of the kidney is the nephron (1). The essential parts of the nephron 
include the renal corpuscle (glomerulus and Bowman’ capsule), the proximal tubule, the 
thin and thick ascending and descending limbs of the loop of Henle, the distal tubule and 
the connecting tubule (1). The remaining collecting duct system is an important segment 
for urine concentration but is not strictly considered part of the nephron structure. The 
glomerulus is a capillary extension consisting of a network of thin blood vessels, lined by 
a thin layer of endothelial cells. The glomerulus acts as the filtration apparatus in the 
kidney and consists of three filtration layers. The glomerular endothelium has many pores 
in the range of 80-100 nm and forms the first filtration layer (2). Immediately beneath the 
endothelium is the glomerular basement membrane (GBM), a 300- to 350 nm-thick basal 
lamina rich in heparin sulfate and charged proteoglycans with an average pore size of 3 
nm (2-4). Behind the GBM are the visceral epithelial cells of the Bowman’s capsule 
called the podocytes, which form the third layer of the filter (4). The glomerular filtration 
apparatus, taken in its entirety acts as a semi-permeable membrane, allowing the passage 
of molecules based on shape, charge and, most importantly, size. The molecular weight 
cut off of the filtration apparatus is about 70,000 Daltons (2). Hence, cells and large 
proteins such as albumin are mostly retained whereas smaller molecules such as amino 
acids, glucose and ions pass through the filter freely. The filtered fluid that is produced as 
a result of glomerular filtration is called the ultrafiltrate. The components of the 
ultrafiltrate are essentially the same as those of blood plasma except that it contains no 
cells and large proteins. The ultrafiltrate flows into the proximal tubules.  
 11 
 
 The proximal tubules consist of an initial convoluted portion called the pars convulata 
and a straight portion called the pars recta (1). Further subdivision based mostly on 
structural criteria has led to the identification of three distinct segments - S1, S2 and S3 
(1, 5). The pars convulata located at the renal cortex comprises of the S1 and S2 
segments. The pars recta, located at the outer medulla, is represented by a small fraction 
of the S2 (continuing from the pars convulata) and mostly the S3 segment. The proximal 
tubular cells (PTC) form a simple epithelium lining the proximal tubule. In the S1 
segment, they have a tall brush border and a well-developed vacuolar lysosomal system. 
The PTC in the S1 segment also possess large basal and smaller apical lateral processes 
which interdigitate with processes of adjacent cells forming a basolateral intercellular 
space. This space is separated from the tubular lumen by tight junctions containing the 
protein zonula occludens (ZO)-1. In the S2 segment, the brush border is shorter and the 
endocytic compartment is less prominent. However, there are numerous small lateral 
processes near the base of the cells. In the S3 segment, there are very sparse lateral cell 
processes and invaginations. 
 
The PTC are not only structurally specialized but also carry out diverse homeostatic, 
metabolic, endocrinologic and probably also immunomodulatory functions (1, 6-15). The 
proximal tubular epithelium is also in close proximity to the peritubular capillary network 
and this is where majority of the exchange of compounds between the tubular fluid and 
blood occurs (1). The exchange occurs through both active and passive processes. The 
active transport system is mediated primarily by ATPases. One of the most important 
 12 
ATPases in the nephron is the Na+/K+- ATPase located at the basolateral membrane of 
the PTC. The Na+/K+-ATPase drives Na+ reabsorption by the PTC from the ultrafiltrate 
and maintains a high K+ concentration and low Na+ concentration in the intracellular 
environment (16, 17). The active transport of Na+ out of the cell across the basolateral 
membrane generates a lumen-to-cell concentration gradient. The energy stored in this 
steep Na+ gradient can be used to drive Na+- linked transporters. One such transporter is 
the Na+/H+ exchanger located in the brush border membrane which couples influx of Na+ 
with the efflux of H+ (16, 17). This mediates acidification of the tubular fluid and 
generates a H+ gradient, which can be used to drive other transport processes. In addition, 
since Na+ is the principal osmole in the extracellular fluid, such transport mechanisms in 
the PTC are critical for the maintenance of extracellular fluid volume.  
 
The primary anion for Na+ is Cl- and the reabsorption of equivalent amounts of Na+ and 
Cl- by the PTC enables regulation of osmotic pressure in our body (16). Cl- is reabsorbed 
mainly by sodium dependent Cl-/HCO3- and Cl-/HCOO- antiporters in the apical 
membrane of the PTC (2, 16).  The Cl-/HCO3- transporter mediates in influx of Cl- from 
the lumen into the PTC and efflux of HCO3- into the lumen. HCO3- is essential for acid-
base balance and pH control in our body. Hence, reabsorption of HCO3- back to the PTC 
and to the circulation is also critical. In fact, the PTC reabsorbs approximately 80% of the 
filtered HCO3- (1). Bicarbonate reabsorption is mediated by an electrogenic Na+/ HCO3- 




In addition to these active transport systems, passive transport mechanisms along a 
concentration gradient also operate simultaneously to facilitate reabsorption from the 
ultrafiltrate.  PTC are responsible for reabsorption of 70% of the filtered water. This is 
mediated mainly through the water channels, in particular aquaporin-1 (AQP1), which is 
expressed in high abundance on the apical and basolateral membranes of the PTC (1, 18, 
19). Approximately 40 % of the sodium chloride is also transported passively (16). Ca2+ 
and Mg2+ are key components of the bony skeleton. In addition, Ca2+ acts as an 
extracellular and intracellular signal. Mg2+ is an essential cofactor for several metabolic 
enzymes and key regulator of ion channels. These two divalent cations are reabsorbed in 
the PTC primarily passively, although the cellular mechanisms behind Mg2+ remain 
controversial (1, 20). Phosphate is important for the bony skeleton, metabolic processes, 
phosphorylation and constitution of nucleic acids. Several sodium-phosphate (Na-Pi) 
cotransporters enable PTC to absorb 80% of the filtered phosphate (1, 21, 22). Sodium 
transport is not only coupled with the transport of inorganic solutes, but also organic 
anions and cations, glucose and amino acids.  
 
In addition, PTC play a crucial role in the excretion of xenobiotics and of several 
commonly used drugs such as antibiotics, non-steroidal anti-inflammatory drugs, loop 
diuretics and immunosuppressive drugs (8, 23, 24). Excretion of such drugs and other 
xenobiotic compounds such as alkaloids, heterocyclic dietary constituents and 
environmental toxins are mediated by organic anion transporters (OATs), in particular 
OAT1 and OAT3 and organic cation transporters (OCTs), primarily OCT1 and OCT2 (8, 
23, 24).  
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Glucose reabsorption in the PTC occurs in two steps: 1) through Na+-glucose co-
transporters 1 and 2 (SGLT1 and SGLT2; most widely characterized and studied) across 
the apical membrane followed by 2) facilitated glucose transport through specific carriers 
in the basolateral membrane belonging to the GLUT family (GLUT1 and GLUT2 most 
widely characterized and studied) (1, 7). Amino acids are reabsorbed in the PTC through 
amino acid transporters such as BºAT1 (system Bº), which transports mostly neutral 
amino acids and  PAT1 which is a H+ co-transporter of proline, glycine and aniline (1). 
Proton-coupled peptide transporter 2 (PEPT2) in the apical membrane of the PTC is 
responsible for H+ co-transportation of di- and tri- peptides (25). The larger proteins and 
polypeptides, as well as hormones and polybasic drugs are reabsorbed by PTC by a very 
well-studied synergistic multiligand endocytic receptor system, megalin and cubulin (26-
28).   
 
In summary, PTC are important for reabsorption of glucose, proteins, amino acids, small 
solutes and water from the ultrafiltrate, for the excretion of xenobiotics, drugs and other 
organic compounds and for the regulation of the concentrations of ions and homeostasis 
(1, 6-8, 10, 15, 16, 18, 19, 23, 29, 30). In addition, PTC have several important metabolic 
functions. For instance, the proximal tubule is the major site of ammonia production in 
the kidney . Ammonia is produced in a pH-dependant manner from the metabolism of 
glutamine. At physiological pH, ammonia combines with H+ to form NH4+, which is 
secreted into the tubular lumen and eventually excreted into the urine. Metabolism of 
glutamine also produces HCO3- which is returned to the blood through the HCO3- 
reabsorption processes discussed earlier. Secretion of H+ and pH-dependant 
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ammoniagenesis together with reabsorption of HCO3- enables the PTC to regulate the 
acid-base balance in our body. For example, acidosis increases H+ secretion, HCO3- 
reabsorption and ammoniagenesis (31).  In this manner, the pH of the plasma and the 
urine is tightly controlled by the PTC. Another important function of the PTC is the 
metabolism of glutathione by gamma glutamyl transpeptidase (GGT) (32). GGT transfers 
the glutamyl moiety from the glutathione to a variety of acceptor molecules including 
water, amino acids, and peptides. The transfer results in the formation of cystein, a thiol 
compound exerting antioxidant effects. This preserves intracellular homeostasis of 
oxidative stress (33). Furthermore, PTC produce the most active form of vitamin D: 1,25-
dihydroxy vitamin D3 (11). It has also been suggested that PTC have immunomodulatory 
functions (12, 14, 34, 35).  PTC might function as specific target cells during allograft 
rejection (36) and can be induced to express major histocompatibility complex class I and 
class II antigens and adhesion molecules (34, 36, 37). PTC might also be involved in 
antigen presentation (38) and might interact with other cells in the renal cortex in 
producing or responding to costimulatory cytokines, i.e. tumour necrosis factor alpha(35). 
In addition, PTC produce interleukin-6 in response to inflammatory cytokines (12). 
However, most of these studies were performed in vitro. The in vivo significance or 
clinical relevance of these results is yet to be elucidated.   
  
Nevertheless, given the wide spectrum of functions of the PTC, it is not surprising that 
several kidney disorders are linked to disorders of the PTC (1, 15, 39). In addition, PTC 
are the most abundant cell type in the kidney (15, 39). Several inherited and acquired 
acid-base disorders and global dysfunction of the proximal tubule are related to impaired 
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transporters in the PTC (39-43). For example, impaired glucose transport due to 
malfunction of SGLT1 and SGLT2 have been suggested as the cause for glucose-
galactose malabsorption and renal glycosuria (41, 42). Similarly, Fanconi-Bickel 
syndrome is caused by impaired inherited GLUT2 function (44). Since GLUT2 is 
responsible for the transport of glucose from the PTC back to the blood, malfunction of 
this transporter leads to glucose accumulation in the PTC and glycotoxicity. Familial 
renal hyporicemia is an inherited disorder characterized by impaired urate handling in 
renal tubules (1). Mutations in the sodium bicarbonate symporters and chloride 
bicarbonate exchangers have been reported for causing proximal renal tubular acidosis 
(1).  PTC also play an important role in the pathophysiology of diabetic mellitus which 
can eventually lead to diabetic nephropathy (1, 45, 46).  
 
In addition to disorders related to transporter malfunction, it has been suggested that PTC 
have intrinsic immune characteristics which enable them to function as immune 
responders to a wide range of immunologic, ischemic or toxic injury (12-14). Therefore, 
it is not surprising that proximal tubule-related phenomena strongly correlate to the 
pathogenesis of a vast array of acute and chronic kidney diseases (1, 39). Furthermore, 
the proximal tubule is responsible for production of the most active form of vitamin D: 
1,25-dihydroxy vitamin D3 (47, 48) and erythropoietin production is also related to 
proximal tubule function (49). Thus, proximal tubule degeneration also contributes to two 
complicated consequences of chronic kidney disease: mineral-bone disorder and anemia. 
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Due to the wide variety of functions and roles in the pathophysiology of several diseases, 
renal PTC are considered one of the most important cell types for kidney tissue 
engineering. Also, due to the function of renal tubular epithelial cells in glomerular 
filtrate concentration and drug transport (1, 15), in particular the renal PTC are a major 
target of drug-induced toxicity. Therefore, this cell type is very important for in vitro 
toxicology studies (50-52). However, approved in vitro models based on renal cells have 
not been developed yet and this remains a major challenge.  For applications of PTC to in 
vitro nephrotoxicology, it has been found that cell lines show reduced sensitivity to toxins 
and toxic effects of nanoparticles (53), as compared to primary human cells. It has been 
suggested that the use of primary cells might be more appropriate (50, 53) . In addition, 
due to interspecies variability, it would be important to use primal renal proximal tubular 
cells of human origin. Therefore, human primary renal proximal tubular cells (HPTC) 
would be most suitable for such applications. 
 
However, the application of primary human cells is also associated with a variety of 
issues, which must be carefully addressed. The costs of the primary cells are substantially 
higher and the culturing conditions are often more complicated; but more importantly, 
primary cells show interdonor variability (53-56). In addition, the properties of primary 
cells change during passaging, and cells become increasingly senescent. Furthermore, 
dedifferentiation or transdifferentiation processes can occur during the in vitro culture of 
primary cells (50, 54, 57-59). These different variables can have an impact on the 
sensitivity of the cells, and thus, thorough characterization of the cells is essential for 
applications in in vitro toxicology and kidney tissue engineering.  
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One of the most important applications of HPTC is bioartificial kidney (BAK) 
development. (60-62). Only this cell type has been approved for clinical applications (61, 
63). BAKs containing HPTC have already been developed (62, 64); however, the work 
and the results detailed in the following section suggest that there were significant 
challenges with the cell-containing cartridges and BAKs in clinical trials. These issues 
will be discussed in more details in the following section. 
 
1.2 Development of BAKs and applications of HPTC in such devices 
Acute renal failure (ARF) affects 5-7% of hospitalized patients and up to 30% of patients 
in intensive care units. The most widely applied therapy for kidney failure involves 
treatment with an artificial kidney. Despite considerable improvement in artificial kidney 
technology during the past decades, the mortality rate of critically ill patients with ARF 
remains 50-70% (65). This suggests that artificial kidneys can not provide some essential 
functions provided by the kidney. In addition, the mortality and morbidity of patients 
with end stage renal disease (ESRD) remain high (66). Although survival advantages of 
transplantation are evident (67-69), high rates of organ rejection and lack of kidneys 
available for transplant still remain the major bottlenecks.  
 
The vast majority of the ESRD patients rely on traditional in-center hemodialysis, which 
is usually performed three times per week for several hours during daytime. These kinds 
of treatment are not only expensive and compromise the quality of life, but also lead to 
periodic accumulation of fluid, uremic toxins and metabolic wastes. Portable and 
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wearable devices allow for more frequent or continuous home-based therapies and hence 
a more normal lifestyle. Portable devices for home hemodialysis are already available 
(70, 71). In addition, successful human pilot studies have been performed with wearable 
artificial kidneys (72-74).  
 
Although these are very promising developments in the field, portable or wearable 
devices only perform clearance of some uremic toxins and volume control, but would not 
compensate for the additional functions performed by the kidney. As artificial kidneys 
are unable to provide the complex functions of the kidneys, development of BAKs as 
proposed by Aebischer and colleagues in 1987, and first in vitro studies on the 
development of such devices were performed (75-78). The BAKs based on this concept 
would consist of a conventional synthetic hemofilter (mimicking glomerular functions), 
connected in series with a bioreactor. The bioreactor would contain hollow fiber 
membranes into which PTC are seeded (75). The bioreactor unit containing proximal 
tubule-derived cells has also been called a renal tubule assist device (RAD) and is 
supposed to replace renal proximal tubular functions. 
 
Following the initial BAK development by Aebischer and colleagues, research on BAKs 
has been continued mainly by two groups since the late 1990s: the group led by Akira 
Saito at the Tokai University School of Medicine (Kanagawa, Japan) and the group led 
by H. David Humes at the University of Michigan (USA). Studies involving animal 
models of acute renal failure (ARF) have shown that treatment with BAKs can improve 
cardiovascular performance, the levels of inflammatory cytokines, and survival time (63, 
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79-81). Following the promising animal trials, the first Phase I/II clinical trial with BAKs 
was performed by the group of H. David Humes in 2004 (64). HPTC were employed in 
the clinical trials. The trial was performed with 10 critically ill patients with ARF, and the 
data showed that the device was sufficiently safe. However, significant changes of 
parameters, which should be influenced by the HPTC included in the device, were not 
observed. For example, active HCO3- transport along the HPTC should result in a decline 
in pH of the ultrafiltrate. Vitamin D regulation by the HPTC should result in an increased 
level of 1,25-dihydroxyvitamin D in plasma. But the data revealed that there were no 
significant changes in the pH of the ultrafiltrate or in 1,25-dihydroxyvitamin D levels 
(64). Analysis of change in serum levels of five cytokines tested showed that the levels of 
granulocyte colony-stimulating factor, interleukin-6 and interleukin-10 were significantly 
changed in a subset of patients. Although these alterations suggest a less proinflammatory 
state of the patients, this only applied to a subset of patients and thus was not conclusive.  
 
Subsequently a multicenter, randomized, controlled, open-label Phase II clinical trial was 
performed in 2004/2005 (62). This study enrolled 58 critically ill patients with ARF with 
the goal of comparing 72 hours of continuous venovenous hemofiltration (CVVH) with 
RAD (40 patients) and without RAD (18 patients). The study analyzed effects on 28-day 
survival as the primary outcome and on 180-day survival. Time to recovery of kidney 
function, time in intensive care unit and hospital discharge and safety parameters were 
also examined. The results indicated that the survival was slightly improved in patients 
receiving CVVH plus RAD treatment. However, only the long-term survival (180 days) 
was significantly improved (62). This trial, in combination with the first clinical trial was 
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a major progress in the field but was also heavily criticized (82). One point raised was 
that the study was severely underpowered (82). Also, only 10 of 40 patients who were 
randomly assigned to CVVH + RAD completed the planned 72 hours of therapy. The 
reports of the study did not discuss the rationale for discontinuing the RAD intervention. 
In addition, it was difficult to comprehend how long-term survival could be improved 
with no significant short-term effects, particularly when the maximum treatment period 
was 72 hours. 
 
A follow-up Phase IIb bridging study enrolling 53 patients was discontinued in 2006 after 
an interim analysis stating that the study would probably not meet its efficacy goal as 
discussed in (62). The first publication on the device used in the Phase IIb clinical trial 
with BAKs, (which had been discontinued) consisted of data only from a control 
subgroup (83). Compelling data regarding the cell containing RAD treated group was not 
published. Overall, the results suggested that there were several challenges with BAKs in 
clinical trials.  
 
The distinguishing factor between BAKs and hemofiltration devices is the bioreactor unit 
containing renal cells. As explained above, renal proximal tubule-derived cells have been 
used in BAK-related research, and for the clinical trials of BAKs, primary HPTC have 
been used. However, most preceding in vitro and animal studies with BAKs were done 
with porcine primary renal proximal tubule cells (79, 80, 84) or cell lines like the 
proximal tubule-derived cell line Lewis lung cancer-porcine kidney 1 (LLC-PK1) (29, 
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75-77, 85-87). Also, immortalized renal cells of unclear origin such as Madin-Darby 
canine kidney (MDCK) cells were used (75). 
 
There are challenges associated with extrapolating results obtained with animal cells/cell 
lines. Animal cells/cell lines (MDCK/LLC-PK1) show different requirements for growth 
and differentiation compared to HPTC. For example, HPTC in the BAK grow on hollow 
fiber membranes. Commercial hemodialysis/hemofiltration cartridges with extracellular 
matrix (ECM) - coated hollow fiber membranes consisting of 
polysulfone/polyvinylpyrrolidone (PSF/PVP) have been applied in BAKs in clinical 
trials, where HPTC were used (62, 64). However, our recent studies demonstrated that 
MDCK and LLC-PK1 cells form differentiated epithelia on different membrane materials 
including hollow fiber membranes consisting of PSF or PSF/PVP (61), but no such 
results could be obtained with HPTC (88, 89). HPTC would not grow and survive on 
such membranes, regardless of whether they were coated with an ECM or not (88, 89). 
More recent results demonstrated that the stiffness of the underlying substrate has 
substantial impact and HPTC performance is compromised on compliant membrane 
materials, which cannot be improved by single ECM coatings (88, 90). Thus, HPTC were 
also unable to grow well on polyethersulfone/polyvinylpyrrolidone (PES/PVP) 
membranes, although MDCK formed confluent epithelia on these materials (61, 88, 91) . 
Hence the results suggest that membrane materials and coatings applied in BAK so far 
might be suitable for animal cells/cell lines, but are not suitable for HPTC. 
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As mentioned above, the commercial hollow fiber membranes used in animal studies and 
clinical trials of BAKs have also been coated with ECMs, which consisted of collagen IV 
and laminin (62-64, 79, 80, 84). Indeed, systematic characterization of different ECM 
coatings in our lab has revealed that collagen IV and laminin are optimal for HPTC, when 
combined with a suitable stiff substrate such as tissue culture plastic (59). Thus, HPTC 
formed well-differentiated epithelia when cultured on plates coated with collagen IV or 
laminin. However, even on such suitable substrates, differentiated epithelia could not be 
maintained for prolonged time periods (59). This was due to monolayer disruption and 
trans-differentiation of a part of the HPTC into -smooth muscle actin (SMA)-expressing 
myofibroblasts (59), which do not form a functional epithelium, as required in BAKs. 
Furthermore, we discovered that the monolayer disruption was due to reorganization of 
the epithelium and formation of tubules (92).  
 
Critical for applications of HPTC in BAK would be to identify conditions which enable 
the maintenance of well-differentiated HPTC epithelia for prolonged time periods. One 
approach is the addition of growth factors to HPTC. Bone morphogenetic proteins 
(BMPs), in particular BMP-7 and bone morphogenetic factor-2 (BMP-2), are interesting 
candidates, based on their known effects on renal cells and tubule formation (93-95). In 
the following section, these growth factors, their effects on renal cells and possible 





1.3 Genetic Engineering of HPTC and development of a BMP-7-producing BAK 
BMPs are members of the transforming growth factor (TGF)-β superfamily. In vitro, 
BMP-7 counteracts epithelial-to-mesenchymal transition (EMT) of mouse-derived renal 
epithelial cell lines and the human immortalized PTC cell line HK-2 (96, 97), which leads 
to the generation of myofibroblasts (98). However, one recent study suggested that this 
does not apply to HPTC (99). Previous studies also reported concentration-dependent 
effects of BMP-7 on renal branching morphogenesis in mouse embryonic explants and on 
tubule formation by collecting duct-derived cells in vitro in three-dimensional gels (93-
95). These studies indicated that higher concentrations of BMP-7 typically inhibited 
tubule formation, whereas low concentrations (< 0.5 nM) had stimulatory effects. Similar 
results were obtained after treatment with BMP-2. Together these findings suggest that 
transdifferentiation of HPTC and tubulogenesis (59, 92), which should be inhibited in 
BAKs, could probably be inhibited by application of BMPs. 
 
Apart from the interesting effects on renal cells and tubulogenesis, BMP-7 has been 
FDA-approved for the treatment of human bone disease (release from local implant). 
There is also an increasing interest in the use of BMP-7 for the treatment of other human 
diseases, including kidney disease. In the adult body, the kidney is the major source for 
BMP-7, and BMP-7 is essential for kidney development (100, 101). Decline in 
expression levels of BMP-7 has been associated with kidney injury or disease (102-105).  
 
Treatment with BMP-7 inhibited or reversed fibrosis and other disease symptoms in 
experimental models of acute or chronic kidney injury, accelerated the restoration of 
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kidney functions, improved survival and had beneficial effects on renal osteodystrophy 
and vascular calcification associated with chronic kidney disease (96, 104, 106-113). 
These results suggest that BMP-7 might have a beneficial effect if used in the treatment 
of human kidney disease. 
 
So far, there are problems with the systemic delivery of BMP-7, which would be required 
for the treatment of kidney patients. The serum half-life of purified recombinant BMP-7 
is about 30 minutes and therefore BMP-7 therapy would require frequent administration. 
The costs associated with this kind of treatment would be very high. A BAK containing 
renal cells could be used for the production of BMP-7, which could be delivered to 
kidney patients during BAK treatment. As HPTC do not produce BMP-7, genetic 
engineering of HPTC would be required. If BMP-7 should have positive effects on the 
HPTC (see above) and have inhibitory effects on transdifferentiation and tubulogenesis, 
the BMP-7 produced in the device would also help to improve cell performance by 
paracrine/autocrine signaling. Therefore, I investigated the effects of commercial human 
recombinant BMP-2 and BMP-7 on HPTC. In addition, I generated BMP-7-producing 
HPTC by genetic engineering and characterized the effects of HPTC-produced BMP-7.  
 
In addition to BMP-7, one would expect that other growth factors also regulate the 
performance of HPTC. In order to learn more about such growth factors, co-culture 
systems would be useful. Co-culture systems for identifying and analyzing such growth 
factors and their effects on HPTC are detailed in the following section. 
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1.4 Co-culture systems  
There is a great interest in tissue models that contain more than one cell type (114, 115) 
and co-culture systems have been frequently investigated. In particular, co-culture 
systems between endothelial cells and other cell types have been addressed (116-124). 
More frequently, co-cultures between endothelial cells and hepatocytes were studied 
(121-124). It has been shown that hepatocyte functions can be improved in co-cultures 
with endothelial cells (121, 122). This is particularly important because primary 
hepatocytes readily de-differentiate under in vitro conditions and this is one of the major 
obstacles for in vitro applications.  
 
The underlying reason behind such a great interest in tissue models that contain more 
than one cell type is that a multiple cell type-system enables the study of cells in an 
environment more similar to that in the human body. In the kidney, for example, the 
endothelial cells of the peritubular capillaries and the renal tubular epithelial cells are 
closely apposed (1, 15).  The tubular epithelium and the peritubular endothelium are not 
only functionally linked under normal conditions, but both play also key roles in diabetic 
and non-diabetic kidney disease (125-129). However, they are separated by the tubular 
basement membrane, a narrow interstitial region containing microfibrils, and the capillary 
basement membrane. Thus, it would be expected that these two cell types communicate 
mainly via soluble factors.  
 
Endothelial cells have also been shown to impact the performance of renal proximal 
tubule cells in vitro. For instance, bovine aortic macrovascular cells regulate PTC sodium 
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transport (116). In addition, various co-culture models have been used to investigate the 
crosstalk between endothelial and renal epithelial cells (116-120). However, specific 
factors secreted by endothelial cells that affect renal cell performance have not been 
reported.  
 
Therefore, in my thesis, I developed and characterized co-culture systems in order to 
identify factors secreted by human umbilical vein endothelial cells (HUVEC) and human 
renal glomerular endothelial cells (HRGEC) which might improve HPTC performance. I 
also analyzed the effects of such factors on HPTC. In addition to identification of growth 
factors, the co-culture systems can also be used for studying the communication between 
renal tubular epithelial and endothelial cells in renal disease and repair. Furthermore, 













2. Hypotheses and Goals 
Goals of my thesis were to: 
 1) a) Establish procedures for the isolation of HPTC from human renal tissues and b) 
characterize  the isolated cells and commercial HPTC by immunostaining, 
immunoblotting, qPCR and functional assays. A thorough analysis and characterization 
of this primary cell type obtained from different donors and sources is essential for 
standardized applications of this cell type in in vitro systems and for the interpretation of 
results. 
2) Characterize the effects of BMPs on HPTC performance. The hypothesis was that 
BMP-2 and/or BMP-7 might inhibit epithelial to mesenchymal transition and 
tubulogenesis of HPTC. Thus, supplementation with these growth factors might help to 
improve HPTC performance in in vitro applications.  
3) In case that the effects of BMPs on HPTC would be positive, my next goal was to 
engineer and characterize BMP-producing HPTC for applications in BAK. It was 
proposed that the performance of such cells would be improved by paracrine/autocrine 
signaling.  
4) Furthermore, HPTC secreting BMP-7 could be used to engineer a BMP-7-producing 
BAK and to deliver the growth factor to kidney patients. As outlined, there is increasing 
interest in BMP-7-based therapies for kidney patients, but cost-effective ways for 
systemic delivery are not available. 
4) Establish and characterize a co-culture system of HPTC and endothelial cells. The 
hypothesis was that endothelial cells secrete growth factors that impact HPTC 
performance.  Thus co-culture systems could be used to identify respective growth 
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factors. Supplementation of HPTC with these growth factors might help to improve 
HPTC performance in applications in kidney tissue engineering and in vitro toxicology. 
Identifying such factors would also help to understand the cross-talk between HPTC and 
endothelial cells, which plays an important role in the kidney during normal function and 




















3. Materials and Methods 
3.1 Isolation of HPTC  
HPTC were either purchased or isolated. For isolation of HPTC, fresh normal human 
kidney tissues were obtained from National University Hospital (NUH), a member of 
National University Health System (NUHS). The use of human renal tissue for primary 
culture was reviewed and approved by the Institutional Review Board (Domain Specific 
Review Board Approval No. E//11/143). The kidneys were removed surgically by 
nephrectomy because of renal cancer. Segments of renal cortex were obtained from the 
normal pole of adult human kidneys through Tissue Repository (NUHS). The kidney 
tissues were screened by the pathologist and only normal sections, as judged by the 
pathologist, were used for isolation of HPTC.  
 
All procedures were performed using aseptic techniques. Upon removal of the tissue, it 
was placed in ice-cold cell culture medium (Dulbecco's Modified Eagle's Medium 
(DMEM)/Ham’s F12 (Invitrogen, Carlsbad, CA, USA)) containing transferrin (5 μg/ml), 
insulin (5 μg/ml), hydrocortisone (0.02 μg/ml), epidermal growth factor (10 ng/ml), 
prostaglandin E1 (0.05 μg/ml), selenium (3.95 ng/ml), tri-iodothyronine (3.36 pg/ml) and 
antibiotics (penicillin/streptomycin) (1%). All these components were obtained from 
Sigma-Aldrich, Singapore. The kidney tissue was transferred to the laboratory on ice. 
The capsule was removed and cortical tissue was dissected from the kidney section and 
HPTC were isolated according to the procedures described in (130). Briefly, the kidney 
cortex was minced finely with a sterile razor. The minced tissue was washed thrice in ice 
cold phosphate-buffered saline (PBS) by centrifugation at 2700 rpm for 5 minutes at 4ºC. 
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The resultant pellet was resuspended in 15 ml of 1.2 mg/ml of class 2 collagenase (315 
U/mg, Worthington Biochemical Corporation, Lakewood, NJ, USA) and incubated for 15 
minutes at 37º C with shaking. The collagenase digestion step was performed twice to 
ensure complete digestion. The digested tissue was passed through a strainer of mesh size 
of approximately 100 m and washed with ice cold PBS three times.  The filtration using 
the strainer ensures removal of any undigested fibrous tissue. After the last wash, the 
pellet was resuspended in 50 ml of 45 % Percoll solution (Invitrogen) pre-diluted with 
ice-cold PBS.  The resuspended pellet was transferred to Beckman tubes for Percoll 
gradient centrifugation at 20,000 rpm for 34 minutes at 4ºC. After centrifugation, 
proximal tubule fragments form a band near the base of the gradient (just above the fat 
cells and red blood cells). This band containing HPTC was transferred to a fresh tube and 
washed twice with ice cold PBS followed by a final wash with cold DMEM/Ham’s F12. 
After the final wash, the cells were plated in a T75 flask containing complete cell-culture 
medium (described above). 0.5 % fetal bovine serum (FBS) (Invitrogen) was used for 
overnight cell attachment whereas at all other times, cells were kept in serum-free culture 
conditions. 
 
Confluent cultures of freshly isolated HPTC were sub-cultured for at least two passages 
before they were frozen to ensure enough stocks of cells. Standard sub-culturing 
procedures were used. This included washing with PBS, cell detachment with 0.05 % 
trypsin (Invitrogen) and neutralization with complete DMEM/Ham’s F12 media 
containing 5% FBS. Freshly isolated HPTC were frozen in complete DMEM/Ham’s F12 
media containing 10 % FBS. Frozen cells were thawed when the cells were required for 
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experiments. Since most cells were frozen after the second passage, cells used for the 
experiments were mostly at passage number four. Cells beyond passage number five 
were not used for any of the experiments.   
 
3.2 Static culture of commercial HPTC 
Commercial HPTC were obtained from ScienCell Research Laboratories (Carlsbad, CA, 
USA) and the American Type Culture Collection (ATCC, Manassas, VA, USA) and were 
cultivated as recommended by the vendors. HPTC from ScienCell Research Laboratories 
were cultivated in basal epithelial cell medium supplemented with 2% FBS and 1% 
epithelial cell growth supplement (ScienCell Research Laboratories). HPTC from ATCC 
were cultured in renal epithelial cell basal medium supplemented with 0.5% FBS and 
renal epithelial cell growth kit-BBE (ATCC). Cell culture media were supplemented with 
1% penicillin/streptomycin (ScienCell Research Laboratories) and cells were cultivated 
at 37ºC in a 5% CO2 atmosphere. All cells were kept subconfluent during growth. 
Similar to the freshly isolated HPTC, commercial HPTC were also frozen. Frozen cells 
were thawed when required for experiments. Most cells were used at passage three or 
four.   
 
3.3 Static culture of myoblasts, fibroblasts and endothelial cells 
C2C12 cells (mouse myoblast cell line) and NIH/3T3 fibroblasts were obtained from 
ATCC and grown in DMEM with 10% FBS. When the effects of HPTC-produced BMP-
7 on C2C12 cells were tested, C2C12 cells were cultivated for 1 day in unconditioned 
HPTC medium, followed by a 3-day incubation period in HPTC-conditioned HPTC 
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medium (as used for HPTC from ATCC) containing HPTC-secreted BMP-7. No 
morphological changes of C2C12 cells were observed when these cells were cultivated in 
HPTC medium. HUVEC and HRGEC were obtained from ScienCell Research 
Laboratories and cultivated in basal endothelial cell medium with 1% endothelial cell 
growth supplement (ScienCell Research Laboratories) and 5% FBS. Cell culture media 
were supplemented with 1% penicillin/streptomycin (ScienCell Research Laboratories) 
and cells were cultivated at 37º C in a 5% CO2 atmosphere. All cells were kept 
subconfluent during growth.  
 
3.4 Experimental set up of static cell culture 
Experiments with HPTC/endothelial cells co-cultures and control mono-culture 
experiments were performed in 12-well transwell systems (Corning Inc., Corning, New 
York, USA) with polyester inserts with a pore size of 0.4 µm. With the exception of the 
co-culture experiments, all other experiments were performed with 24-well cell culture 
plates (Nunc, Naperville, IL, USA) unless stated otherwise. On day 0 of each experiment, 
cells were seeded at almost confluent density: 8×104 cells/cm2 for HPTC and 5×104 
cells/cm2 for HUVEC, HRGEC, fibroblasts and C2C12. The cell culture medium was 
exchanged every two days during the experimental series. 
 
3.5 Live/dead assay 
The live/dead assay was performed by adding 2 µl of 5 mg/ml 4’,6’-diamidino-2’-
phenylindole (DAPI) and 2 µl of 1 mg/ml propidium iodide (PI, Invitrogen) solution to 
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each well containing 1 ml of medium. Cells were kept in the incubator for 1–2 h before 
imaging.  
3.6 Bioreactor set up and perfusion culture 
PSF obtained from Sigma-Aldrich and Fullcure™ 720 (FC, PolyJET acrylic-based 
monomer) obtained from Stratasys (Eden Prairie, MN, USA) were used for the 
preparation of Polysulfone–Fullcure (PSF-FC) membranes as described (88). The 
membranes were prepared by Mohammed Shahrudin Ibrahim. The membranes were 
assembled into gradient perfusion bioreactors developed by Mohammed Shahrudin 
Ibrahim and Dr. Rensheng Deng. The PSF-FC membrane separated an upper chamber 
and a lower chamber, and the membrane area for cell growth was 9.6 cm2. The 
bioreactors were sterilized by perfusion of 80% ethanol for 10 min, followed by washing 
with PBS for 30 min and conditioning with HPTC cell culture media for another 30 min. 
The lower chamber was filled with 4 ml of cell culture medium. 4 ml of HPTC 
suspension containing 4×105 cells/ml were injected into the upper chamber. The cell-
seeded bioreactors were incubated for 5 h at 37º C in a 5% CO2 atmosphere under static 
conditions and were perfused afterwards at a rate of 80 ml/min. Perfusion was performed 
for 4 days before the functional assays were carried out on day 5 after cell seeding. 
During the 4-day perfusion period, a closed circuit was used, with a total medium volume 
of 300 ml. Functional assays were performed with an open circuit. All functional assays 
were done at least in triplicates.  
 
3.7 Treatment with recombinant BMP-2 and recombinant BMP-7 
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Lyophilized commercial human recombinant BMP-7 and BMP-2 (Miltenyi Biotec, 
Bergisch-Gladbach, Germany) were reconstituted in PBS. In static cultures, the growth 
factors were added during cell seeding, and cells were constantly kept in growth factor-
supplemented medium unless otherwise indicated. In bioreactor experiments HPTC were 
seeded and perfused with BMP-7-containing medium (25 ng/ml). 
 
3.8 Treatment with human recombinant TGF-β1 and human recombinant A2M 
Lyophilized commercial human recombinant TGF-β1 (R&D Systems, Minneapolis, MN, 
USA) and human recombinant A2M (Abcam, Cambridge, UK) were reconstituted in 
sterile water. HPTC medium was supplemented with 630 pg/ml of TGF-β1 and 3.7 ng/ml 
of A2M during cell seeding. These concentrations were equivalent to the concentrations 
of these factors in HUVEC co-cultures, as determined by enzyme-linked immunosorbent 
assay (ELISA). The cells were constantly kept in supplemented medium.  
 
3.9 Immunostaining and quantification of fluorescence intensities 
Immunostaining was performed after formaldehyde fixation of cells. Fixation was 
performed with 3.7% formaldehyde (Merck, Darmstadt, Germany) in PBS for 10 min at 
room temperature, followed by extensive washing with PBS. Fixed samples were always 
kept wet. Following fixation, unspecific antibody binding was blocked using 5% bovine 
serum albumin (BSA) (Sigma-Aldrich) dissolved in PBS containing 0.1 % Tween-20 
(Sigma-Aldrich) and 0.1 % Triton X-100 (Merck). Blocking was performed for 1 h at 
room temperature. Primary antibodies were obtained from Santa Cruz Biotechnology, 
Inc, CA, USA, unless stated otherwise. The following primary antibodies were used for 
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HPTC: rabbit anti-ZO-1 (Invitrogen), mouse anti-α-SMA (Abcam, Cambridge, UK), 
mouse anti-E-cadherin (E-CAD, Abcam), mouse anti-CD13 (Abcam), mouse anit-
Uromodulin 10 (URO-10), mouse anti-Na+/K+ ATPase, rabbit anti-N-cadherin (N-CAD), 
rabbit anti-AQP1, rabbit anti-OAT3, rabbit anti-megalin and mouse anti-Tamm Horsfall 
glycoprotein (THG) (Cedarlane, Burlington, Ontario, Canada). Primary antibodies 
against phosphorylated Smad2/3 (Ser 423/425) and phosphorylated Smad1/5/8 (Cell 
Signaling Technology, Danvers, MA, USA) were used for C2C12 cells. Cells were 
incubated with primary antibody overnight at 4ºC. Following primary antibody 
incubation and washing with PBS, secondary antibodies were applied. Alexa Fluor 488-
conjugated anti-rabbit (Invitrogen) and TRITC-conjugated anti-mouse (Invitrogen) 
secondary antibodies were applied to detect the primary antibodies. After 
immunostaining, cell nuclei were stained with DAPI and cells were mounted with 
Vectashield (Vector Laboratories, Burlingame, CA) for microscopy. Classification of 
ZO-1 immunostaining patterns was performed as described in (59). An Olympus BX-
DSU microscope (Olympus, Tokyo, Japan) equipped with Metamorph 7.5.6.0 software 
(Silicon Valley, CA, USA) was used for epifluorescence imaging. Images were taken 
from randomly selected areas of the wells, and the same exposure time was used in all 
cases. Adobe Photoshop CS3 10.0.1 was used for image analysis. For quantification of 
immunofluorescence of phosphorylated Smad1/5/8, the areas covered by cell nuclei were 
identified by the DAPI staining, and the average relative fluorescence intensities (Alexa 
Fluor 488) in these areas were determined. The average fluorescence intensities in the 
areas outside of the nuclei were used for background correction. 
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3.10 Immunoblotting  
α-SMA levels and various marker protein expression in HPTC were quantified by 
immunoblotting. Cells were lysed in sodium dodecyl sulfate (SDS) lysis buffer 
(Invitrogen) containing 50 mM of tris hydroxymethyl aminomethane (Tris, Invitrogen). 
The protein concentration was measured with a Nanodrop spectrophotometer (Thermo 
Scientific, Wilmington, DE, USA). Equal amounts of protein were loaded onto each lane 
of the gel separated using the NuPage system (Invitrogen) under reducing conditions (0.1 
M Dithiothreitol, Fermentas, Burlington, Canada) according to manufacturer’s 
instructions. After electrophoresis, proteins were transferred to polyvinylidene fluoride 
membranes using the iBlot system (Invitrogen), which were then blocked in Tris-buffered 
saline (TBS; 0.14 M sodium chloride, 0.003 M potassium chloride and 0.025 M  Tris 
base) containing 1% of Tween-20 (TBS-T) and 10% of BSA. Blocking was performed at 
room temperature for 2 h. The membranes were then incubated with primary antibodies 
overnight at 4°C. The following primary antibodies were used: rabbit anti-BMP-7 
antibody (LifeSpan BioSciences, Seattle, WA, USA), mouse anti-α-SMA, rabbit anti-α-
tubulin, mouse anti-E-CAD, mouse anti-CD13 (antibodies from Abcam), mouse anti-
Na+/K+ ATPase, rabbit anti-N-CAD, rabbit anti-AQP1 (antibodies from Santa Cruz 
Biotechnology, Inc.) and mouse anti-THG (Cedarlane). Rabbit anti-α-tubulin antibody 
was used at a dilution of 1:5000 and the remaining primary antibodies were used at a 
dilution of 1:500. The primary antibodies were detected using donkey anti-rabbit and 
sheep anti-mouse horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare, Buckinghamshire, UK) at a dilution of 1:5000. Primary and secondary 
antibodies were diluted in blocking buffer. The membranes were washed with TBS-T, 
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and the blots were developed using the ECL detection kit (GE Healthcare). The 
chemiluminescence signal was captured on X-ray films, which were scanned and 
analyzed using Adobe Photoshop CS3 10.0.1.  
3.11 ELISA 
The levels of BMP-7, TGF-β1 and A2M in the culture medium were quantified by using 
ELISA kits specific for human BMP-7 (RayBiotech, Inc., Norcross, GA, USA), human 
TGF-β1 (Abfronitier, Seoul, Korea) and human A2M (Abnova, Taipei, Taiwan) 
respectively. The assays were performed according to manufacturers’ instructions. 
 
3.12 Quantitative real-time polymerase chain reaction (qPCR) 
qPCR was performed three days after cell seeding. In cases where the HPTC or C2C12 
cells were treated with BMP-7 or HPTC-conditioned medium containing HPTC-secreted 
BMP-7, qPCR was performed three days after cell treatment. Total RNA was extracted 
by lysing the cells with TrizolTM (Invitrogen). The total amount of RNA was determined 
using a NanoDropTM  ND-1000 Spectrophotometer. The SuperScriptTM III First-Strand 
Synthesis System (Invitrogen) was used to perform cDNA synthesis, and qPCR was 
conducted using a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA). Primer sequences are provided in the Tables 1-3. The expression levels of all 
marker genes were normalized to the expression levels of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).  
Marker / Gene Primer Pairs Amplicon (bp)  
E-CAD/ CDH1 F 5'-GAGGACCAGGACTTTGACTT-3' 107 
 R 5'-AGATACCGGGGGACACTCAT -3'   
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N-CAD / CDH2 F 5'-CCCATACACCAGCCTGGAACGC-3' 80 
 R 5'-TGGGTCGGTCTGGATGGCGA-3'   
ZO-1 / TJP1  F 5'-GAGAGGATTTGTCCGCTCAG-3' 86 
 R 5'-AGGCCTCAGAAATCCAGCTT-3'   
CD13 / ANPEP F 5'-CACACACCGTTCCTGGATCTCCTCT-3' 76 
 R 5'-GCTCCAACAGGCGAAGGTCACT-3'   
SGLT2 / SLC5A2 F 5'-ACGCCTGATTCCCGAGTTCT-3' 110 
 R 5'-AGAACAGCACAATGGCGAAGT-3'  
GGT / GGT1 F 5'-TGAGCCCAGAAGTGAGAGCAGTTG-3' 85 
  R 5'-ATGTCCACCAGCTCAGAGAGGGT-3'   
PEPT1 / SLC15A1  F 5'-GCAGGGGCAGGCCAGTTCAG-3' 70 
 R 5'-AGACGACCAGAAGCAACGCGG-3'   
PEPT2 / SLC15A2 F 5'-GGATCAGCAGGGTTCACGAT-3' 100 
 R 5'-GGGATTTAGAACCTGCATCT-3'   
GLUT5 / SLC2A5 F 5'-CCCCAGCTCTTCATCACTGTTGGC-3' 148 
 R 5'-TTTGGAACACAAGGAGGGGGCC-3'   
OAT1 / SLC22A6 F 5'-TCTACTCCTGGTTCTTCATTG-3' 142 
 R 5'-CGGAGTACCTCCATACTCAAT-3'   
OAT3 / SLC22A8 F 5'-GCCCTTGGACTTGCAGACCG-3' 127 
 R 5'-ACCTGTTTGCCTGATGACTG-3'   
OCT1 / SLC22A1 F 5’-GCCGAGAACCTTGGGAGAA-3’ 110 
 R 5’-CACGACATCGCCGCAAA-3’  
OCTN2 / SLC22A5 F 5’-GGTTTGGCCGGAAGAATGT-3’ 120 
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 R 5’-CCATGCCTACAAGGACAAACAG-3’  
AQP1 / AQP1  F 5’-AAGCTCTTCTGGAGGGCAGT-3’ 137 
 R 5’-CACCTTCACGTTGTCCTGGACCG-3’   
Na+/K+ ATPase /  F 5’-GCTGACCCGCCATCGCCAT-3’ 114 
ATP1B1 R 5’-ACCAACTGCCACCGGTCCTG-3’   
NBC1 / SLC4A4 F 5'-CCAAACTGGAGGAGCGACGGAAG-3' 90 
 R 5'-CACACACATGCTTGAGGAAGGA -3'   
Vit D3 Hydr /  F 5'-TTTGGCCCAGATCCTAACACA-3' 76 
CYP27B1 R 5'-AGTCCGGGTCTTGGGTCTAAC-3'   
α-SMA / ACTA2 F 5’-TCATCACCAACTGGGACGAC-3’ 80 
 R 5’-ATGCTCTTCAGGGGCAACAC-3’   
Vimentin / VIM F 5'-ACCTGAGGGAAACTAATCTG-3' 105 
 R 5'-CGTTGATAACCTGTCCATCT-3'   
MDR1 / ABCB1 F 5’-GCCCTTGTTAGACAGCCTCATATTT-3’ 141 
 R 5’-GGACAGGCGGTGAGCAAT-3’  
GAPDH / GAPDH F 5’-TTGACGCTGGGGCTGGCATT-3’ 157 
 R 5’-GTGCTCTTGCTGGGGCTGGT-3’  
Table 1: Details of primer pairs for human marker genes and human GAPDH for 
analyzing gene expression in HPTC. The sequences of the primer pairs (forward: F, 
reverse: R) are shown. The sizes of the amplicons are provided in base pairs (bp). Primers 
amplifying genes coding for the following proteins were used: E-CAD, N-CAD, ZO-1 (or 
tight junction protein 1 TTJP1)), CD13, SGLT2, GGT, proton-coupled peptide 
transporters 1 and 2 (PEPT1 and PEPT2), glucose transporter 5 (GLUT5), OAT1, OAT3, 
OCT1, organic cation/carnitine transporter 2 (OCTN2), AQP1, Na+/K+ATPase, 
Na+HCO3- cotransporter 1 (NBC1), 25-hydroxyvitamin D3 1 -hydroxylase (Vit D3 






Marker / Gene Primer Pairs Amplicon (bp)  
Osteocalcin /  F 5’-CGCCTACAAACGCATCTATGG-3’ 
 
90 
BGLAP R 5’-CCCGGAGAGCAGCCAAA-3’  
Osteopontin / SPP1 F 5’-CTGTGGACTCGGATGAATCTGA-3’ 
 
100 
 R 5’-GGGACGATTGGAGTGAAAGTG-3’  
RUNX2 / RUNX2 F 5’-AGGGTGGCCATTATGACTCTTATC-3’ 119 
 R 5’-CCACGAAGCCTGCAATTTAGA-3’  
Osterix / SP7 F 5’-CCCCCAAGGAAATTCTAGTCAA-3’ 120 
 R 5-CAACCCAAAACTCAACTGAAAAAGA-3’  
Alk. phosphatase / 
ALPL F 5’-GGCCTGGATCTCATCAGTATTTG-3’ 80 
 R 5’-AGTTCAGTGCGGTTCCAGACA-3’  
DMP1 / DMP1 F 5’-CTGAAGAGAGGACGGGTGATTT-3’ 81 
 R 5’-GGCTAGCTTGACTTTCTTCTGATGA-3’  
PHEX / PHEX F 5’-ACCAGACTCTACCCACACTTGAAAG-3’ 100 
 R 5’-CGGCACCTAATATCCTAAACAAATC-3’  
GAPDH / GAPDH F 5’-ATCCCAGACCCCCATAATAACA-3’ 80 
 R 5’-TGCAGCGAACTTTATTGATGGT-3’  
Table 2: Details of primer pairs for murine osteogenic markers and murine GAPDH. 
Primers amplifying genes coding for the following proteins were used: bone gamma 
carboxyglutamate protein (BGLAP, also called osteocalcin), secreted phosphoprotein 1 
(SPP1, also called sialoprotein or osteopontin), runt-related transcription factor 2 
(RUNX2), Sp7 transcription factor 7 (SP7, also called osterix), alkaline phosphatase, 
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liver, bone, kidney (ALPL), dentin matrix protein 1 (DMP1), and phosphate-regulating 
gene with homologies to endopeptidases on the X chromosome (PHEX). 
 
Marker  Primer Pairs Amplicon (bp)  
VEGF-A F 5’- GCACCCATGGCAGAAGGAG-3’ 107 
 R 5’- TCCACCAGGGTCTCGATTG-3’  
VEGF-B F 5’- CCCTGTCTCCCAGCCTGAT-3’ 71 
 R 5’- CGCGAGTATACACATCTATCCATGA-3’  
VEGF-C F 5’- CAAGGCCCCAAACCAGTAAC-3’  
 
61 
 R 5’- TAGACATGCATCGGCAGGAA -3’  
FGF-2 F 5’- TGTGCTAACCGTTACCTGGC-3’ 148 
 R 5’- CGTTTCAGTGCCACATACCAA-3’  
IGF-1 F 5’- CTAAGGAGGCTGGAGATGTATTGC-3’ 64 
 R 5’- ACGGACAGAGCGAGCTGACT-3’  
HGF F 5’- GCCTGCTGTCCTGGATGATT-3’ 68 
 R 5’-TTTCAGGAATTGTGCATCCATAA -3’  
TGF-β1 F 5’- ACCTGAACCCGTGTTGCTCT-3’ 128 
 R 5’-GCTGAGGTATCGCCAGGAAT-3’  
PDGF-A F 5’- TTGGCCACCTTGACGCT-3’ 224 
 R 5’- CCTGCCCATTCGGAGGAA-3’  
PDGF-B F 5’- TTTCTCACCTGGACAGGTCG-3’ 226 
 R 5’- GAAGGAGCCTGGGTTCCCT-3’  
A2M F 5’- GAAGGGCCATTTTTCCATCTC-3’ 58 
 R 5’- CCGAGCGACAGGAGCAAT-3’  
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DCN F 5’- TCCTGATGACCGCGACTTC-3’  84 
 R 5’- GAACACTGGACCACTCGAAGATG-3’  
FST F 5’- CGAGGAGGACGTGAATGACA-3’ 57 
 R 5’- GCGCCCCCGTTGAAA-3’  
FSTL3 F 5’- GCCGCCAGGTGGTGAGT-3’ 60 
 R 5’- CCTGCAGGCTCACACGAA-3’  
VEGFR-2 F 5’- GAGGGACTTGGACTGGCTTTG-3’ 67 
 R 5’- CTCAGTCACCTCCACCCTTTG-3’  
FGFR-2 F 5’- GAAGTGCATACACCGAGACCTG-3’  133 
 R 5’- TCGGCCGTTGGTTGTCTT-3’  
TGFβR-1 F 5’- AGCGGTCTTGCCCATCTTC-3’ 65 
 R 5’- CTATGAGCAATGGCTGGCTTT-3’  
Table 3: Details of primer pairs used for the qPCR analysis of HUVEC gene expression. 
The sequences of the primer pairs (forward: F, reverse: R) are shown. The sizes of the 
amplicons are provided in base pairs (bp). Primers amplifying genes encoding for the 
following secreted factors were used: VEGF-A, -B and -C, fibroblast growth factor 
(FGF)-2, insulin-like growth factor (IGF)-1, hepatocyte growth factor (HGF), TGF-β1, 
and platelet-derived growth factor (PDGF-A and PDGF-B). In addition, primers 
amplifying genes encoding for the following TGF-β1 antagonists were used: A2M, 
decorin (DCN), follistatin (FST), and follistatin-like 3 (FSTL3). Furthermore, primers 
amplifying genes coding for the following receptors were used: VEGF receptor 2 
(VEGFR-2), FGF receptor 2 (FGFR-2), and TGF-β1 receptor 1 (TGF-R1).  
 
3.13 Determination of GGT activity 
In order to determine the activity of the brush border enzyme GGT, cells were incubated 
with phenol red-free media. For measuring GGT activity in static culture, the cells were 
cultivated for at least 3 days after seeding. Cells had formed a confluent monolayer after 
~ 1 day. The cells were then incubated for 1 h with 1 mM of γ-glutamyl-p-nitroanilide 
(Sigma-Aldrich) and 20 mM of glycyl-glycine (Sigma-Aldrich). After 1 h, 10% acetic 
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acid was added to stop the enzymatic activity. The absorbance at 405 nm was measured 
using a microplate reader (Tecan Safire 2TM, Männedorf, Switzerland) in order to 
determine the concentrations of p-nitroaniline. The concentrations of p-nitroaniline 
measured in the individual wells were normalized to their protein content. The protein 
content of each sample was determined by using the Bradford assay (Bio-Rad 
Laboratories, Hercules, CA, USA).  
 
To determine the GGT activity of HPTC in PSF membrane bioreactors (details in Section 
3.6), the cells were perfused for 4 h with an open circuit with phenol red-free medium 
containing 1 mM of γ-glutamyl-p-nitroanilide and 20 mM of glycyl-glycine for 
conditioning. After the conditioning period, the medium was collected at the outlet during 
the following hour. In addition, samples were taken at the inlet. The absorbance of the 
collected medium was measured at 405 nm. The GGT activity of cells was calculated 
from the standard curve, which was based on known concentrations of p-nitroaniline 
(Merck). The GGT activity was normalized with either cell numbers or total protein 
content.  
 
3.14 Determination of leucine aminopeptidase (LAP) activity 
The activity of the brush border enzyme LAP was determined as described in (131). 
HPTC were cultivated for at least 3 days after seeding. Cells formed a confluent 
monolayer after ~ 1 day. The cells were then incubated for 1 h in PBS containing 1 mM 
L-leucine-p-nitroanilide at 23ºC. After the incubation period, absorbance at 405 nm was 
measured using a microplate reader in order to determine the concentrations of p-
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nitroaniline. The concentrations of p-nitroaniline measured in the individual wells were 
normalized to their protein content. The protein content of each sample was determined 
by using the Bradford assay. 
 
3.15 Determination of the response to parathyroid hormone 
The response of cells in static culture to parathyroid hormone (PTH) and arginine 
vasopressin (AVP) was determined after overnight treatment of cells with medium 
containing 0.1 mM of 3-isobutyl-1-methylxanthine (IBMX) (Merck) and exposure of 
cells to 100 nM and 1000 nM of human PTH (Sigma-Aldrich) and human AVP (Sigma-
Aldrich) for 30 minutes at 37°C. The cells were extracted with 0.1 M hydrochloric acid 
(Merck), and the intracellular concentration of cyclic adenosine monophosphate (cAMP) 
was determined using the cAMP direct immunoassay kit (Calbiochem, San Diego, USA). 
The Bradford method was used to quantify the amounts of proteins in cell extracts, and 
the cAMP concentrations were normalized to the amounts of protein. The response of 
HPTC in perfusion culture to PTH was determined similarly with the exception that the 
incubation with PTH was carried out for 3 h instead of 30 minutes and the cells were kept 
under perfusion conditions in bioreactors containing PSF membranes (Section 3.6). 
 
3.16 Determination of alkaline phosphatase (AP) activity 
To determine the osteogenic activity of BMP-7, the murine myoblast cell line C2C12 was 
used and the AP activity was measured. The cells were seeded in triplicates in 96-well 
plates at a seeding density of 5 × 104 cells/cm2. The cells were either untreated (control), 
or treated with 25 ng/ml or 100 ng/ml of commercial BMP-7 (Miltenyi Biotech). 
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Alternatively, C2C12 cells were treated with conditioned medium from transduced BMP-
7-producing HPTC. Viral titers were adjusted in a way that the conditioned medium from 
transduced HPTC contained 25 ng/ml or 100 ng/ml of BMP-7. BMP-7 concentrations in 
the conditioned medium were determined by ELISA. The conditioned medium or the 
medium supplemented with commercial BMP-7 was changed every day. After 3 days, the 
AP activity of C2C12 cells was measured.  
 
Cell layers were extracted with 20 nM of TBS (pH 7) containing 1% Triton X-100. 10 
mM of p-nitrophenyl phosphate (Merck) in 50 mM of sodium carbonate buffer (pH 10) 
with 5 mM of magnesium chloride was used as a substrate. The absorbance was 
measured at 405 nm following 30 min of incubation at 37°C. The concentration of the 
reaction product p-nitrophenol was determined using a standard curve. The amount of 
protein in each sample was measured using the BCA protein assay kit (Pierce, Rockford, 
IL, USA). The measured amount of p-nitrophenol was normalized to the protein content. 
The AP activity in HPTC and fibroblasts was measured using the same protocol. 
 
3.17 Generation of BMP-7-producing HPTC using non-viral systems 
The following transfection regents were used according to manufacturers’ instructions: 
LipofectamineTM 2000 (Invitrogen), Genejuice and Nanojuice (Novagen, Madison, WI, 
USA) MetafecteneTM Pro (Biontex laboratories GmbH, Planegg/Martinsried, Germany), 
Fugene 6 and Fugene HD transfection reagents (Roche, Basel, Switzerland), Attractene 
(Qiagen, Hilden, Germany), Xtremegene High Performance (HP) transfection reagent 
(Roche) and Geneporter 3000 (San Diego, CA, USA). The DNA: transfection ratios were 
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optimized and the transfection efficiency was tested using the GFP-expressing 
pBudCE4.1 mammalian vector (Invitrogen) and the pmaxFP-Green-C mammalian 
expression vector (Lonza, Basel, Switzerland) according to manufacturers’ instructions. 
Generally, at least 0.8 g of DNA was used for each  transfection and DNA: transfection 
reagent ratios of 1:1 to 1:4 were tested. HPTC were seeded two days before transfection 
and transfection was carried out when the cells were approximately 80%-90% confluent. 
Transfections were always carried out in serum-free and antibiotics-free media. Cells 
were checked for GFP expression 24 h, 48 h and 72 h after transfection. Transfected cells 
were stained with DAPI and PI to analyze cytotoxicity caused by the transfection. The 
percentage of dead cells was calculated by expressing total number of PI-stained cells as 
a percentage of total number of DAPI-stained cells which were counted using Image J 
1.4.  
 
In addition to commercial transfection reagents, polymer-based gene delivery systems 
developed by Dr. Yi Yan Yang’s group at IBN were also tested. Electroporation was 
carried out using a Pipette Type Electroporator (Microporator System, Digital Bio 
Technology Co., Ltd, Suwon, Korea) and pulse width, voltage and number were 
optimized according to manufacturer’s instructions.  
 
The level of BMP-7 produced by transfected HPTC was measured after transfecting 
HPTC with BMP-7 expressing mammalian vector pReceiverM02 (GeneCopoeia, Inc., 
Rockville, MD, USA). Secreted BMP-7 was measured by ELISA.  BMP-7 was cloned 
into the high expression vector pcDNA3.1 (Invitrogen) using standard cloning 
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procedures. Briefly, BMP-7 was amplified from pReceiverM02-BMP-7 by PCR using 
primers containing BamHI and Not I overhangs. The PCR product and the vector 
(pcDNA3.1) were digested with BamHI and Not I (Fermentas) and ligated with T4 DNA 
Ligase (Fermentas). The ligation reaction was transformed into DH5 chemically 
competent E.Coli cells (Invitrogen) according to manufacturer’s instructions. Colonies 
were screened using restriction digestion and DNA sequencing. A positive clone was 
selected for DNA isolation and used for transfection. 
 
A BMP-7 gene with improved properties (BMP-7 construct # 3392) as described in (132) 
was synthesized by Genscript Inc. (Piscataway, NJ, USA). The improved gene was 
further codon-optimized by Genscript Inc. and supplied in pcDNA3.1 vector.  
 
3.18 Generation of BMP-7-producing HPTC using a lentiviral system 
A lentiviral vector expressing human recombinant BMP-7 under the cytomegalovirus 
(CMV) promoter (EX-A0309-Lv105) was obtained from GeneCopoeia, Inc.. The 
lentiviral vector was available on filter paper discs, which were incubated in 50 μl of 
water for 1 h. Clones were then transformed into One Shot® Stbl3™ chemically 
competent E. coli cells (Invitrogen) according to manufacturer’s instructions. Colonies 
were screened using polymerase chain reaction (PCR) and DNA sequencing. A positive 
clone was transfected into human embryonic kidney (HEK) 293T cells (packaging cell 
line, ATCC) using EndoFectin Lenti transfection reagent (GeneCopoeia Inc.). The 
transfection was carried out according to manufacturer’s instructions. Briefly, the 
packaging cells were incubated with DNA EndoFectin Lenti complex and HIV packaging 
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mix at 37°C in a CO2 incubator. Following overnight incubation, the culture medium was 
replaced with fresh medium supplemented with 5% FBS and 1/500 volume TiterBoost 
(included in the kit). Incubation was continued for another 48 h, and pseudovirus-
containing culture medium was collected and centrifuged to remove cell debris. Finally, 
the supernatant was filtered through 0.45-μm polyethersulfone low-protein binding 
filters. Aliquots of the virus were stored at -80°C. The viral titer used to transduce HPTC 
was optimized such that the BMP-7 level (measured by ELISA) 24 h after transduction 
was the same as the BMP-7 level in cultures treated with 25 ng/ml or 100 ng/ml of 
commercial BMP-7. ELISA was performed with the fresh conditioned medium directly 
obtained from the transduced cells and no storage of the conditioned medium occurred. 
Independent ELISA experiments confirmed that the desired concentration of BMP-7 was 
reproducibly obtained when the same experimental conditions were applied (identical 
viral stock and viral titer were always used). After confirming the reproducibility of the 
results by ELISA, the functional assays were performed with fresh conditioned medium 
containing the HPTC-produced BMP-7. The conditioned medium was directly applied to 
C2C12 cells or HPTC and no storage of the conditioned medium occurred.   
 
3.19 Statistics 
The unpaired t-test was used for statistics. In the figures, significant differences are 







4.1. Isolation of HPTC and characterization of freshly isolated and commercial HPTC  
4.1.1 Isolation of HPTC 
HPTC are available commercially and were being used in our lab. However, this allows 
only limited control over the quality and pre-treatment of the cells. In addition, HPTC 
dedifferentiate and transdifferentiate under in vitro conditions and this depends, at least in 
part, on the actual in vitro culturing conditions (59, 92). Therefore, for applications in in 
vitro toxicology and BAK development, in addition to the commercial HPTC, it was 
important to prepare our own isolates. This would allow better control over culturing 
conditions, pre-treatment and purity. In order to obtain our own HPTC isolates, normal 
human kidney tissues were obtained after nephrectomy. HPTC were successfully isolated 
using the procedures described in the materials and methods section. Freshly isolated 
HPTC were seeded into a tissue culture flask (T75) and took about 6 days to reach 
confluence. Confluent monolayers showed the characteristic “cobblestone” morphology 
(Fig. 1). 
 
Figure 1: Phase contrast image of confluent freshly isolated HPTC.  Human renal 
cortical tissues were collected from tumor nephrectomies and HPTC from areas with 
normal tissue were isolated by Percoll gradient centrifugation. Confluent HPTC formed a 
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tight monolayer with the characteristic epithelial “cobblestone” morphology. Scale bar: 
100 µm. 
For applications in in vitro systems, it is important to ensure that the HPTC are relatively 
pure and in a well-differentiated state. Therefore, I characterized the differentiation 
status, functional properties and expression of epithelial and HPTC-specific markers of 
both our own isolates of HPTC and commercial HPTC (ATCC). The analysis also 
included markers specific for other renal cell types in order to address contaminations 
with other cell types and potential changes in marker expression patterns under in vitro 
conditions. Experiments were performed with three batches of freshly isolated and 
commercial HPTC to ensure that differences in results were not due to interdonor 
variability. The characterization was carried out using immunostaining, immunoblotting, 
functional assays and qPCR.  
 
4.1.2 Characterization of HPTC by immunoblotting  
First, I determined the expression of markers in freshly isolated and commercial HPTC 
by immunoblotting. The expression of epithelial markers specific for distal tubular cells 
(E-CAD) and proximal tubular cells (N-CAD) and of the brush-border enzyme CD13 
(aminopeptidase N, proximal tubule-specific) was analyzed (Fig. 2). In addition, 
expression of the Na+/K+ATPase (expressed in proximal tubules and other renal cell 
types), AQP1 (proximal tubule-specific) and the distal tubule marker THG was 
determined. 
 
The results showed that HPTC from both sources expressed very low levels of N-CAD 
(Fig. 2). The expression of N-CAD in our own isolates was so low that the band was not 
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discernable when the X-ray filmed was scanned to produce the image. Our own isolates 
expressed relatively high amounts of distal tubule specific E-CAD which was expressed 
at much lower levels in commercial HPTC. The results also showed that both commercial 
and freshly isolated HPTC expressed the distal tubule-specific marker THG and proximal 
tubule-specific markers CD13 and AQP1 (Fig. 2).  The Na+/K+ATPase, which is 
important for many transport processes, was also consistently expressed. 
 
 Together, the results showed that both proximal and distal tubular markers were 
expressed in HPTC from both sources. This suggests two possibilities: 1) the cells 
represented a mixture of proximal and distal tubular cells in culture or 2) the cells were 
relatively pure but developed a mixed expression pattern in vitro.  
 
Figure 2: Immunoblotting with antibodies against various marker proteins. The lanes 
were loaded with lysates from freshly isolated HPTC (lanes 1 and 2) and commercial 
HPTC from ATCC (lanes 3 and 4). In all cases -tubulin was used as the loading control. 
The positions of the 25 kDa, 50 kDa, 100 kDa and 130 kDa size marker bands were 
indicated. 
 
4.1.3 Characterization of HPTC by qPCR 
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In addition to my immunoblotting studies, I determined gene expression patterns of 
HPTC by qPCR in collaboration with my colleague Dr. Karthikeyan Kandasamy. The 
marker genes tested included the genes for the epithelial markers E-CAD, N-CAD and 
ZO-1, as well as the genes coding for the brush border enzymes CD13 and GGT (Fig. 3). 
The expression of genes coding for GLUT5, AQP1, Vit D3 Hydr and the Na+/K+ ATPase 
was also assessed (Fig. 3). The results showed that expression of AQP1, CD13, ZO-1 and 
GLUT5 were higher in freshly isolated HPTC compared to commercial HPTC. The 
expression levels of GGT and Na+/K+ ATPase were similar in both.  The results also 
showed that both E-CAD and N-CAD were expressed in HPTC from the two sources. In 
addition, E-CAD expression was higher and N-CAD expression was lower in freshly 
isolated HPTC. Consistent with the immunoblotting results, also these qPCR results 
suggested that either there was a mixed population of cells in culture or the cells had 
heterogeneous marker expression. In order to address these possibilities, immunostaining 
and functional assays were applied to further characterize the cells.  
 
 
Figure 3: Gene expression levels of freshly isolated and commercial HPTC determined 
by qPCR. Bars show the average ± SD (n = 3). The gene expression levels of Vit D3 
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Hydr in both freshly isolated and commercial HPTC and AQP1 in commercial HPTC 
were very low and thus the bars were not discernable. Data for freshly isolated HPTC 
were obtained from Dr. Karthikeyan Kandasamy. 
 
4.1.4 Characterization of HPTC by immunofluorescence 
Although immunoblotting and qPCR are useful for quantification of protein and gene 
expression, it would be important to determine the expression patterns of individual cells 
in order to confirm whether there were indeed two different populations of cells or 
whether individual cells had a mixed expression pattern. Therefore, the markers assessed 
by immunoblotting were also analyzed for immunofluorescence (Fig. 4). In addition, 
expression of the epithelial markers ZO-1 (tight junction protein) and URO-10 (proximal 
tubule-specific), and of the transporters megalin and OAT3 was assessed (Fig. 4).  
 
The results revealed that the markers E-CAD, N-CAD, ZO-1, URO-10, CD13, megalin, 
OAT3, AQP1 and THG were expressed in HPTC from both sources. The Na+/K+ ATPase 
could not be detected by immunofluorescence in commercial HPTC. The 
immunofluorescence of E-CAD and megalin was also very low levels in commercial 
HPTC. Immunofluorescence performed with antibodies against ZO-1, Na+/K+ ATPase, 
OAT3 and megalin resulted in stronger fluorescence in freshly isolated HPTC, as 
compared to commercial HPTC (Fig. 4). The fluorescence with antibodies against THG 
and AQP1 were stronger in commercial HPTC compared to our own isolates and the 
fluorescence levels of CD13 and URO-10 were similar in HPTC from both sources. In 
cases where immunoblotting results were available, the observed relative expression 
levels were in agreement with the results obtained by immunofluorescence. For example, 
higher levels on E-CAD expression in our own isolates were observed by both 
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immunoblotting and immunofluorescent studies. N-CAD expression was observed in 
HPTC from both sources but was higher in commercial HPTC. It should be noted that N-
CAD expression was barely detectable by immunoblotting and thus it was important to 
confirm the expression of this protein by immunostaining. In addition, although Na+/K+ 
ATPase expression was detected by immunoblotting, it could not be detected in 
commercial HPTC using immunofluorescence, likely due to technical problems. Hence, 
immunofluorescence or immunoblotting alone would not be sufficient. 
 
Together these results confirmed that important marker proteins were expressed, but 
showed again that markers specific for both proximal and distal tubular cells were present. 
In order to assess whether different cell types were present or whether individual cells 
displayed mixed expression patterns, I performed double immunostaining of the proximal 
and distal tubule markers, N-CAD and E-CAD. 
 
The results revealed that distinct populations expressing either one or the other marker 
were not present (Figure 5). Rather, individual cells expressed both markers. This 
suggested that both freshly isolated and commercial HPTC were relatively pure and 
showed a mixed marker expression pattern. The double immunostaining was performed 
with our own isolates and could not be performed with commercial HPTC because of 
extremely low levels of E-CAD expression.  Nevertheless, as observed from the 
individual immunostaining patterns of CD13 and THG (Fig. 4), almost all commercial 
HPTC express both CD13 and THG. These results suggest that similar to freshly isolated 
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HPTC, commercial HPTC also showed mixed expression patterns.  However, to further 







Figure 4: Detection of various markers by immunostaining. (A) The first and third 
columns show representative immunofluorescence patterns obtained with antibodies 
against E-CAD, N-CAD, ZO-1, URO-10 and CD-13. The second and fourth columns 
show the expression level of the same proteins as quantified by immunoblotting (Figure 
2). (B) The first and third columns show representative immunofluorescence patterns 
obtained with antibodies against Na+/K+ ATPase, Megalin, OAT3, AQP1 and THG. The 
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second and fourth columns show the expression level of the same proteins as determined 
by immunoblotting (Figure 2). Both isolated and commercial HPTC were seeded 3 days 
prior to fixation for staining or lysis for immunoblotting. Confluent monolayers were 
achieved ~ 1 day after cell seeding. Scale bars: 100 µm. (+) very weak expression; + 







Figure 5: Double-immunostaining of E-CAD and N-CAD in freshly isolated HPTC. The 
upper two panels show immunostaining of N-CAD (green) and E-CAD (red) in the same 
area of cells. The lower panel shows the overlay. Scale bars: 100 µm 
 
4.1.5 Characterization of HPTC by functional assays 
In order to confirm that the cells were of proximal tubule origin, I determined the activity 
of the brush border enzymes GGT, LAP and AP. HPTC were incubated with the GGT 
substrates γ-glutamyl-p-nitroanilide and glycyl-glycine, the LAP substrate L-leucine-p-
nitroanilide and the AP substrate p-nitrophenyl phosphate for determination of the 
respective enzyme activities. The concentrations of p-nitroaniline, which was produced in 
the reactions catalyzed by GGT or LAP, were determined (Fig. 6 A). NIH/3T3 fibroblasts 
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were included as a negative control. In addition, the concentration of p-nitrophenol, 
which was produced in the reaction catalyzed by AP was determined (Fig. 6 B). The 
results showed that both freshly isolated and commercial HPTC showed activity of the 
brush border enzymes GGT, LAP and AP. In the case of GGT and LAP activity, the 
concentrations of p-nitroaniline were much higher compared to the fibroblasts, 
demonstrating the specificity of the reaction. Both GGT and LAP activity were higher in 
the freshly isolated HPTC when compared to the commercial HPTC. On the other hand, 
AP activity was slightly lower in our isolates of HPTC. Fibroblasts also showed AP 
activity, but this is expected as fibroblasts have been reported to show AP activity (133). 
 
HPTC show a dose-dependent increase of the concentration of intracellular cyclic 
adenosine monophosphate (cAMP) in response to treatment with PTH (134). In contrast, 
distal tubular cells increase the concentration of intracellular of cAMP in response to 
arginine vasopressin (AVP) (134). In order to test hormone response in our cells, freshly 
isolated HPTC, commercial HPTC and fibroblasts (negative control) were treated with 
100 nM and 1000 nM of PTH (Fig. 6 C). In addition, to address the potential presence of 
distal tubular cells, response to 100 nM and 1000 nM of AVP was tested. When treated 
with 100 nM and 1000 nM PTH, both freshly isolated and commercial HPTC showed 
increased intracellular cAMP levels compared to non-treated cells (IBMX control). 
Freshly isolated HPTC showed approximately 140-fold and 200-fold increases in cAMP 
levels compared to the IBMX control when treated with 100 nM and 1000 nM of PTH 
respectively.  The fold increase of cAMP was lower in the case of commercial HPTC 
(approximately 27-fold and 16-fold when treated with 100 nM and 1000 nM of PTH 
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respectively). In contrast, upon treatment with 100 nM AVP, cAMP levels were 
increased to approximately 2-fold in both freshly isolated and commercial HPTC as 
compared to IBMX control. This suggests that most of the cells are indeed of proximal 
tubular origin. The results also indicate that the expression of distal tubule markers such 
as E-CAD and THG observed in the immunoblotting and immunofluorescent studies 
were due to mixed expression patterns of the HPTC. This is addressed in further detail in 
the discussion section. 
 
Figure 6: (A) GGT and LAP activity in isolated and commercial HPTC. The activity of 
GGT and LAP was determined by measuring the amount of the reaction product p-
nitroaniline produced by the brush border enzymes (nmol/mg protein/h; mean ± SD, n = 
4; the concentrations measured after an incubation period of 1 h were normalized to the 
protein content of the cell extracts). Fibroblasts (GGT and LAP-negative) were used as 
negative control. (B) AP activity in isolated and commercial HPTC. The amounts of p-
nitrophenol produced during a 30-min incubation period were determined and normalized 
to the protein content of the cell samples. (ng/30min/g protein; mean ± SD, n = 4 ). 
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Fibroblasts were used as control, but also show some AP activity (133) (C) Hormone 
responsiveness of isolated and commercial HPTC. Fibroroblasts served as negative 
control. Intracellular levels of cAMP were measured in pmol/mg protein (mean ± SD, n = 
4; the concentrations of cAMP measured were normalized to the protein content of the 
cell extracts) in response to treatment with PTH, AVP and IBMX control. The cAMP 




In summary, qPCR, immunostaining, immunoblotting and the functional assays together 
demonstrated that the HPTC were functional and expressed epithelial as well as HPTC-
specific markers. In addition, the functional assays and the marker expression patterns 

















4.2 Analysis of factors impacting HPTC performance under in vitro conditions 
Before the commencement of my Phd thesis, I was already working on the optimization 
of HPTC performance in the lab. I started by characterizing HPTC performance on ECM 
coatings. Analyzing effects of ECM components is important because in the kidney, basal 
sides of PTC are attached to a basal lamina. This basal lamina consists of the typical 
major ECM components of basal laminae, namely laminin, collagen IV, entactin/nidogen, 
and perlecan (135, 136). In addition, basal laminae of proximal tubules contain other 
components such as nephronectin, bamacan, agrin, and the tubulointerstitial nephritis 
antigen (135-139). As ECMs regulate cell behavior in a complex manner and affect cell 
adhesion, proliferation, differentiation, migration and survival, one would expect that the 
ECM environment has a major impact on the performance of HPTC. In addition, ECM 
coatings have been used to improve cell performance in BAKs (for details, please see 
Section 1.3). However, their effects on HPTC, which is the most important cell type with 
regard to clinical applications, had not been tested systematically. Also, the effects of 
ECM coatings on cell performance during extended time periods have not been 
addressed. 
 
 My colleague Huishi Zhang and I worked on more than 40 different ECM coatings. The 
best results were obtained with ECMs consisting of the basal lamina components, 
laminin, collagen IV, and a combination of these components (59). Differentiated 
epithelia, with extensive tight junction formation could be maintained for up to three 
weeks on these ECMs (Fig. 7 A, B) (59). However, beyond this time point, monolayer 
disintegration always occurred (59, 92). 
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More detailed analysis of this process of epithelial disruption revealed that α-SMA-
expressing myofibroblasts, which appeared in increasing amounts during the cultivation 
period, seemed to play a crucial role (92). The myofibroblasts formed large aggregates 
(Fig. 7 C, D) and the surrounding epithelium became reorganized. Firstly, movements of 
large numbers of cells led to retraction of the monolayer on one side of myofibroblast 
aggregates, leaving behind the largely empty surface of the well (Fig. 7 E, F). 
Subsequently, the monolayer retracted on the other side of the myofibroblast aggregates. 
These highly coordinated cell movements led to the formation of stripes of cells. The 
cells forming the stripes then performed additional dynamic reorganizations, which gave 
rise to tubule formation with a length of up to several millimeters or even centimeters 
(Fig. 7 G, H, (92)). It would be important to inhibit such processes in the BAK and other 





Figure 7: Formation and disruption of epithelia formed by HPTC on tissue culture plates. 
The left-hand panels (A, C, E, G) show images of live HPTC. Rows B, D, F and H (the 
three panels in each row display the same field of cells) show ZO-1 and α-SMA 
immunofluorescence patterns and the DAPI staining. (A, B) Properly differentiated 
epithelia were formed within the first week after cell seeding. (C–F) The images were 
obtained during the next 1–2 weeks. Increasing numbers of α-SMA-expressing 
myofibroblasts appeared. Large cell aggregates were formed and the epithelium de-
differentiated and was rearranged and disrupted (some areas devoid of cells are labeled 
with arrowheads in E and F). (G, H) Rearrangements led to the formation of renal tubules 
(marked by arrowheads) on the substrate surface. Panels C–H reflected the sequence of 
events, but the different steps were very fast, and tubule formation was often completed 
within one day. After week 1, tubule formation could occur at any time. Scale bars: 100 
μm (A–E), 200 μm (F–H). 
 
Inhibition of tubulogenesis in in vitro systems has been observed previously after 
applying various conditions of BMP-2 and BMP-7 (93-95) . It should be noted here that 
tubulogenesis in these experimental systems occurred by a different process than tubule 
formation on plastic surfaces observed by us (92). BMP-7 has also been shown to inhibit 
EMT and formation of α-SMA expressing myofibroblasts in vitro (93-95, 97, 140) using 
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other renal cell types than HPTC. Therefore, in order to analyze whether treatment with 
BMP-2 or BMP-7 could inhibit EMT and tubulogenesis of HPTC under our conditions, I 






















4.3. Effects of BMP-7 and BMP-2 on HPTC 
4.3.1 Effects of BMP-7 on the maintenance of epithelia formed by HPTC 
First, I investigated whether treatment with BMP-2 or BMP-7 inhibited the disruption of 
epithelia formed by HPTC. Cell behavior was monitored over a period of 4 weeks.  The 
following concentrations of commercial human recombinant BMP-7 were added during 










ZO-1 pattern Disintegration 
of ZO-1 pattern  
BMP-2 650 +  after week 4 1-2 after week 3 
520 + after week 4 1-2 after week 4 
520 ** + after week 1 1-2 after week 1 
390 + after week 4 1-2 after week 4 
312 + after week 3 1-2 after week 3 
260 + after week 3* 4 after week 1 
208 + after week 2 2-3 after week 2 
130 + after week 1 3 after week 1 
26 + after week 1 3 after week 1 
BMP-7 100 + after week 4 1-2 after week 4 
100 ** + after week 1 1-2 after week 1 
75 + after week 4 1-2 after week 4 
50 + after week 4 1-2 after week 4 
25 + after week 4 4-5 after week 4 
12.5 + after week 1 1-2 after week 1 
Table 4: HPTC performance at different concentrations of BMP-2 and BMP-7. “+” 
indicated initial formation of a confluent monolayer. The column “monolayer disruption” 
indicated after which time point the monolayer became disrupted. The classification of 
the ZO-1 immunostaining patterns (pattern types 1–5) was performed as described in 
(59). Only staining pattern types 4 and 5 indicated proper epithelial differentiation and 
tight junction formation. These ZO-1 immunostaining patterns disintegrated at later time 
points, as indicated in the last column. At least three replicates were monitored in each 
case, and most of the experimental series were repeated at least twice with different 
batches of cells.  
** Growth factor added after monolayer formation. 
* Variable results, see text 
Monolayer formation and maintenance were assessed over the monitoring period of 4 
weeks, along with the degree of epithelial differentiation (as revealed by the ZO-1 
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immunostaining patterns) (Table 4). Classification of ZO-1 immunostaining patterns was 
performed as described in (59). Typical chicken wire-like ZO-1 immunostaining patterns 
indicating extensive tight junction formation were classified as types 4 or 5. More diffuse 
ZO-1 immunostaining patterns were classified as types 1–3, and these patterns indicated 
insufficient epithelial differentiation and tight junction formation.  
 
Patterns of types 1–2 revealing insufficient epithelial differentiation were obtained with 
most of the BMP-7 concentrations tested (Table 4). High numbers of α-SMA-expressing 
cells were present in samples displaying insufficient epithelial differentiation (Fig. 8 A). 
However, formation of cell aggregates and tubules did not occur under these conditions, 
and the monolayer was maintained in most samples until the end of the monitoring period 
(Table 4).  
 
In contrast, a well-differentiated epithelium was obtained with 25 ng/ml of BMP-7 (Table 
4, Fig. 8 B), and a relatively low number of α-SMA-expressing cells was observed under 
this condition. No cell aggregate and tubule formation or monolayer disruption was 
observed over the period of 4 weeks, and the epithelia remained intact during the entire 
monitoring period (Table 4). These results showed that treatment with 25 ng/ml of BMP-
7 did not promote the accumulation of myofibroblasts, successfully inhibited the 
disruption of epithelia, and substantially improved cell performance. The study also 




Figure 8: Effects of BMP-7 and BMP-2. Representative images of HPTC exposed to 
different concentrations of BMP-7 and BMP-2 are shown. For each growth factor, 
concentration and cell batch, at least three replicates were tested. Imaging was performed 
2 weeks after cell seeding. The three panels in each row (A–D) display the same field of 
cells. The panels show ZO-1 and α-SMA immunofluorescence patterns and the DAPI 
staining. (A, C) The monolayers display a relatively low cell density, high numbers of 
myofibroblasts and insufficient tight junction formation at high concentrations of BMP-7 
and BMP-2. (B, D) Epithelial differentiation was improved at lower concentrations of 
BMP-7 (25 ng/ml) and BMP-2 (260 ng/ml), and lower numbers of α-SMA-positive cells 
were observed. Scale bar: 50 μm.  
 
To address inter-donor variability the experiments with 25 ng/ml of BMP-7 were 
repeated using different batches of HPTC. The results were consistent for the different 
batches of cells; well-differentiated epithelia could be maintained during the entire 
monitoring period of 4 weeks in all cases (Fig. 9).  
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Figure 9: Treatment with 25 ng/ml of BMP-7 improved the long-term maintenance of 
epithelia. The left-hand panels (A, C, E) show DIC and phase contrast images of live 
HPTC. Rows B, D and F (the three panels in each row display the same field of cells) 
show ZO-1 and α-SMA immunofluorescence patterns and the corresponding DAPI 
staining, as indicated. Rows A/B, C/D, and E/F display cells from three different batches 
of HPTC. For each batch of cells, at least three replicates were tested. All images were 
captured after 4 weeks of in vitro culture. In all cases, properly differentiated epithelia 
could be maintained for this time period, and overall only a few α-SMA-positive cells 
were observed. A higher number of α-SMA-positive cells, a lower cell density and a zig-
zag ZO-1 staining pattern indicated a slightly compromised epithelial differentiation in 
the cell batch displayed in row E/F. Scale bars: 200 µm (A, C, E) and 50 μm (B, D, F). 
 
 
4.3.2 Effects of BMP-2 treatment 
Next, I tested the effects of BMP-2. As summarized in Table 4, at high concentrations of 
BMP-2 of 650 ng/ml (25 nM), 520 ng/ml (20 nM), 390 ng/ml (15 nM) and 312 ng/ml (12 
nM), monolayer disruption was inhibited. However, proper epithelial differentiation did 
not occur, and high numbers of α-SMA-positive cells were observed (Fig. 8 C). 
Disruption of the monolayer was not inhibited when 520 ng/ml of BMP-2 were added 
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only after the epithelium formation or at lower concentrations of 208 ng/ml (8 nM), 130 
ng/ml (5 nM) and 26 ng/ml (1 nM) (Table 4).  
 
The best results in terms of epithelial differentiation were obtained with 260 ng/ml of 
BMP-2 (Table 4, Fig. 8 D) and disruption of the monolayer was delayed at this 
concentration. However, variable results were obtained; inhibition of epithelial disruption 
was only observed in some of the replicates during one experimental series. A high 
degree of variability was also observed with other batches of HPTC. Overall, no 
consistently satisfactory results were achieved with BMP-2.  
 
4.3.3 Quantification of α-SMA expression 
A consistent observation throughout the different series of experiments was the presence 
of increasing numbers of α-SMA-positive cells at higher concentrations of BMP-2 and 
BMP-7 (Fig. 8). Therefore, in order to further address this effect, immunoblotting was 
performed to quantify the levels of α-SMA protein at different concentrations of BMP-2 
or BMP-7 after 2 weeks of treatment. The levels of α-SMA protein were not significantly 
changed in cultures treated with 26 ng/ml of BMP-2 or 25 ng/ml of BMP-7, as compared 
to the untreated controls (Fig. 10 A). Significantly higher levels of α-SMA protein were 
observed after treatment with 100 ng/ml of BMP-7 or 260 ng/ml and 650 ng/ml of BMP-
2. These results showed that the occurrence of α-SMA-expressing myofibroblasts was 
not inhibited by the treatment with low concentrations of BMP-2 and BMP-7, but that 
higher concentrations of these growth factors increased the levels of α-SMA protein.  
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Next, I tested the effects of BMP-7 on α-SMA transcript levels by using qPCR. BMP-7 
was applied at various concentrations ranging between 12.5 ng/ml and 100 ng/ml (Fig. 10 
B). No significant effects of BMP-7 on the expression levels of α-SMA transcripts were 
observed (compared to the untreated control, p > 0.05). These findings confirmed that 
treatment with lower concentrations of BMP-7 does not reduce the expression of α-SMA 
and suggested that the increases of α-SMA protein levels at higher concentrations of 
BMPs were due to post-transcriptional regulatory mechanisms.  
 
Figure 10: Quantification of α-SMA expression. (A) HPTC were exposed to the different 
concentrations of BMP-7 or BMP-2 indicated (x-axis) or left untreated (control). In each 
case, proteins were extracted from 3 replicates of cultures after 2 weeks of in vitro 
culture, and each extract was loaded onto a separate lane of a gel. Immunoblotting was 
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used to detect α-SMA- and α-tubulin-specific bands. Band intensities were determined, 
and the ratios of α-SMA to α -tubulin band intensities were indicated by the bars 
(average ± standard deviation). The relative levels of α-SMA protein in cultures treated 
with 25 ng/ml of BMP-7 or 26 ng/ml of BMP-2 were not significantly different from 
those of the control (p > 0.05). In contrast, significantly increased α-SMA protein levels 
were observed when 100 ng/ml of BMP-7 or 650 ng/ml and 260 ng/ml of BMP-2 were 
applied, as compared to the control, and the cultures treated with 25 ng/ml of BMP-7 or 
26 ng/ml of BMP-2. (B) HPTC were treated with various concentrations of BMP-7 as 
indicated on the x-axis or were left untreated (control). The amounts of α-SMA 
transcripts were determined by qPCR. The bars show the average ± standard deviation (n 
= 3). Significant differences are indicated by *p < 0.05 and **p < 0.001. 
 
4.3.4 BMP-7 enhances cell type-specific functions of HPTC in bioreactors 
So far, the results showed that 25 ng/ml of BMP-7 were most effective in inhibiting 
epithelial disruption without increasing the amounts of myofibroblasts. Next, we asked 
whether 25 ng/ml of BMP-7 improved also other aspects of HPTC performance. The 
experiments were performed under perfusion conditions in bioreactors, where HPTC 
resided on a synthetic polymeric membrane in order to monitor HPTC performance under 
conditions more similar to those in BAKs. First, the activity of the brush border enzyme 
GGT was determined. The bioreactors seeded with HPTC were perfused with cell culture 
medium containing the GGT substrates γ-glutamyl-p-nitroanilide and glycyl-glycine. In 
some experiments, the medium containing the GGT substrates was supplemented in 
addition with 25 ng/ml of BMP-7. The concentrations of p-nitroaniline, which was 
produced in a reaction catalyzed by GGT, were determined in the fresh medium entering 
the bioreactors at the inlet and in the perfused medium collected at the outlet. Significant 
amounts of p-nitroaniline could only be detected when the medium was collected at the 
outlet (Fig. 11 A). The concentration of p-nitroaniline in the medium collected at the 
outlet was significantly increased when the medium was supplemented with 25 ng/ml of 
BMP-7 (as compared to medium not supplemented with BMP-7 (control)) (Fig. 11 A; p < 
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0.05). This result showed that the activity of the brush border enzyme GGT was higher in 
HPTC treated with 25 ng/ml of BMP-7.  
 
HPTC increase the concentration of intracellular cAMP in response to treatment with 
PTH. Figure 11 B shows that HPTC perfused with a medium containing 100 nM of PTH 
showed increased cAMP levels as compared to control cells perfused with non-PTH-
supplemented medium (p < 0.001). Treatment of PTH-exposed cells with 25 ng/ml of 
BMP-7 further enhanced the levels of cAMP (p < 0.001, as compared to the cells treated 
with PTH-supplemented medium without BMP-7). Together, the results showed that 





Figure 11: HPTC performance in bioreactors. (A) Determination of GGT activity. HPTC 
were perfused with a medium supplemented with γ-glutamyl-p-nitroanilide and glycyl-
glycine. In some experiments, the medium was also supplemented with 25 ng/ml of 
BMP-7 (control: medium not supplemented with BMP-7). Samples of the medium fed 
into the bioreactors were collected at the inlets. The perfused medium was collected at 
the outlets for 1 h. The concentration of p-nitroaniline was determined in the collected 
samples. The averages of the results of 5 replicas ± standard deviation (s.d.) are shown. 
(B) Response to PTH. Bioreactors were either perfused with normal medium (control) or 
medium supplemented with 100 nmol/l of PTH. In one experimental series, the medium 
was supplemented with PTH and 25 ng/ml of BMP-7 (3 replicas in each case). After PTH 
treatment, the concentrations of cAMP (pmol) were determined in the cell lysates and 
normalized to the protein concentrations (mg) of the lysates (y-axis). Significant 
differences are indicated by *p < 0.05 and **p < 0.001. 
 
In summary, treatment of HPTC with 25 ng/ml of BMP-7 promoted maintenance of well-
differentiated epithelia and improved the functional performance of HPTC (141). BMP-7 
 76 
can not only be used to improve the performance of HPTC in vitro, but can also be 
applied to HPTC in the BAK. A BMP-7-producing BAK would help to improve HPTC 
performance in the BAK; in addition, the HPTC-produced BMP-7 could also be 
delivered to the patients’ kidneys. Furthermore, such a device would help circumvent the 
challenges associated with systemic administration of BMP-7. Hence, I generated BMP-



















4.4 Generation of BMP-7-producing HPTC for applications in BAK 
4.4.1 Generation of BMP-7-expressing HPTC using a non-viral system 
I first tried to deliver the BMP-7 expression construct using non-viral systems since such 
methods would be most useful for clinical applications. Transfection of primary cells is 
often challenging. Here, I tested 9 different commercial transfection reagents according 
to the protocols described in the Materials and Methods section (3.17). I also optimized 
the transfection protocols by using different DNA: transfection ratios. In addition I 
applied several electroporation protocols detailed in the Materials and Methods section 
(3.17). Furthermore, I tested peptide-based gene delivery systems developed by Dr. Yi 
Yan Yang’s group at IBN. The transfection efficiency was determined by estimating the 
number of GFP-expressing cells compared to the total number or cells after transfection 
with a GFP-expressing mammalian vector. Most of the transfection reagents tested 
showed very low transfection efficiency (Fig. 12 A). The best transfection efficiency was 
obtained when HPTC were transfected using Xtremegene HP (Roche, Basel, 
Switzerland) transfection reagent (Fig. 12 B).  
  
Figure 12: HPTC transfection efficiency. (A) Representative image of HPTC transfected 
with reagents that showed low transfection efficiency. The image displays an overlay of a 
phase contrast image and GFP fluorescence after transfection with a GFP-expressing 
mammalian vector. (B) HPTC transfected with Xtremegene HP transfection reagent. The 
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image shows an overlay of DAPI-stained HPTC (blue) and GFP fluorescence after 
transfection with a GFP-expressing mammalian vector. Both images contain 
approximately same cell numbers since the same seeding density was used for all 
experiments. Images were taken 72 hours after transfection. Scale bars: 100 µm 
 
Since Xtremegene HP demonstrated the best transfection efficiency, this transfection 
reagent was used for all remaining experiments. In order to assess the BMP-7 levels 
produced by the transfected HPTC, I measured the HPTC-produced-BMP-7 by ELISA. 
Since 25 ng/ml was the optimal BMP-7 concentration for HPTC performance, this would 
be the desirable level of HPTC-produced-BMP-7. Therefore, HPTC supplemented with 
25 ng/ml of human recombinant BMP-7 were used as a positive control for the ELISA. In 
addition, cytotoxicity was also analyzed by methods detailed in the Materials and 
Methods section (3.17). Furthermore, in order to confirm the optimal transfection 
conditions, different transfection reagent: DNA ratios were used.   
 
 The best results were obtained when a Xtremegene HP transfection reagent: DNA ratio 
of 1:1 was used (Fig. 13 A). At this ratio, the highest level of BMP-7 production was 
obtained (approximately 10 ng/ml) and the cytotoxicity was the lowest (Fig. 13 B). 
However, the desired level of 25 ng/ml could not be achieved. 
 
It must be noted here that the BMP-7 concentration obtained by ELISA when HPTC were 
treated with 25 ng/ml of human recombinant BMP-7 was approximately 16 ng/ml (Fig. 
13 A). This difference is likely due to the uptake of BMP-7 by the HPTC. I tested this by 
performing ELISA with HPTC treated with 25 ng/ml of human recombinant BMP-7 and 
taking readings at 24 hour intervals for upto 4 days. In addition, I included media 
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containing 25 ng/ml of human recombinant BMP-7 (without any cells). The 
concentration of BMP-7 in the samples without cells was 25 ng/ml at all times. In 
addition, when HPTC were treated with 25 ng/ml of human recombinant BMP-7 and the 
sample was immediately analyzed by ELISA, the concentration remained at 25 ng/ml. 
After 24 hours, it decreased to approximately 16 ng/ml and was maintained at this level 
for upto 4 days.  
 
Figure 13: Levels of BMP-7 produced after transfection of HPTC and cytotoxicity of the 
procedure. (A) HPTC were transfected with Xtremegene HP at different reagent: DNA 
ratios. HPTC supplemented with human recombinant BMP-7 (25 ng/ml) was used as 
positive control and untransfected HPTC was used as negative control. The BMP-7 
concentration was measured by ELISA 72 h post-transfection. (B) Cytotoxicity was 
measured as the percentage of total cells (DAPI-stained) which showed PI staining. hr 
BMP-7: commercial human recombinant BMP-7  
 
Next, I tried to increase the levels of BMP-7 produced by transfected HPTC by cloning 
BMP-7 into the pcDNA3.1 high expression vector (Invitrogen, Materials and Methods, 
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Section 3.17). In parallel, I also used a synthetic BMP-7 gene which contained several 
mutations that could potentially improve the properties of the secreted BMP-7. A 
previous study reported that mutations in amino acid residues at positions 287, 421, 422 
and 462 resulted in the secretion of more soluble mature protein (132).  
 
It should be noted here that BMP-7 is secreted as a stable complex consisting of the 
processed growth factor dimer noncovalently associated with prodomain propeptide 
chains (142). Proteolyitc processing of pro-BMP-7 can occur at four different sites, 
resulting in a number of different mature isoforms of BMP-7 (132). Such heterogeneity is 
undesirable in a protein therapeutic due to inability to fully characterize a polypeptide 
chain and to determine the potential for immunogenicity. Thus mutations at positions 299 
and 314, which were reported to result in a more homogenous protein (132), were also 
included in the synthetic gene.  
 
 The positions of all the mutations I included in the synthetic gene and their expected 
effects are detailed in Table 5. The gene was synthesized by Genscript Inc. (Piscataway, 
NJ, USA) and cloned into the pcDNA3.1 high expression vector.  
Table 5: Changes in amino acid residues of BMP-7 which could potentially improve 
properties of the secreted protein (132). The first character indicates the original amino 
Mutations  Potential Improvement 
R299S/R314S  No N-terminal heterogeneity and production of truncated  
 isoforms of BMP-7 
H287R  Improved accessibility for cleavage of the prodomain 
R421E/N422D/R462E  Increased solubility 
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acid, the number indicates the position of the mutation and the second character indicates 
the new amino acid after mutation. 
 
However, even with the high expression vector and the new synthetic gene in the high 
expression vector, the levels of BMP-7 production were not improved (Fig. 14). The level 
of BMP-7 produced by the high expression vector was approximately 8 ng/ml. When 
HPTC were transfected with the synthetic BMP-7 in the high expression vector, the level 
of BMP-7 produced was very low (Fig. 14). This was an unexpected result. The correct 
DNA sequence of the synthesized gene in the pcDNA3.1 vector was confirmed by 
sequencing. One possible explanation could be that the study which reported the 
mutations and their effects used the Chinese Hamster Ovary (CHO) cell line (132). It is 
possible that the processing of the synthetic gene is different in different cell types.  
 
 
Figure 14: Level of HPTC-produced BMP-7. BMP-7 and synthetic BMP-7 were cloned 
into a high expression vector. BMP-7 concentration was measured by ELISA 72 h post-





4.4.2 Generation of BMP-7-expressing HPTC using a lentiviral system 
According to our results, 25 ng/ml of BMP-7 was the only condition at which HPTC 
performance was improved. For proof of concept it was important to obtain HPTC-
produced-BMP-7 at a concentration of 25 ng/ml. In order to increase the levels of BMP-7 
expression, I delivered the BMP-7 expression construct using a lentiviral transduction 
system. HPTC were transduced with the lentiviral particles and the BMP-7 protein was 
measured using immunoblotting and ELISA. Western blots with an anti-BMP-7 antibody 
performed under reducing conditions with lysates obtained from transduced HPTC or 
with conditioned medium from transduced cells displayed a broad band in the size range 
of ~ 16 kDa (Fig. 15 A). A band in the same size range was obtained with commercial 
BMP-7 (Fig. 15 A). Based on the amino acid sequence, the expected size of the processed 
monomer expressed from the construct used here was 15.6 kDa. The band was intense in 
the lanes loaded with conditioned medium, which showed that the protein was secreted 
into the medium. The broadness of the band indicated the presence different isoforms 
with slightly different sizes.  
 
In addition, I used ELISA to detect BMP-7 in conditioned medium from transduced 
HPTC (Fig. 15 B). The results showed that it was possible to adjust the viral titer in a 
way that the concentration of HPTC-secreted BMP-7 in the medium at 1 day after 
transduction was the same as the BMP-7 concentration in the medium of cultures 
supplemented with 25 ng/ml of commercial BMP-7. Increasing concentrations were 
observed in static cultures after longer incubation periods when the medium was not 
changed (Fig. 15 B).  
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Figure 15: Characterization of BMP-7 expressed by genetically engineered HPTC. (A) 
Western blot performed under reducing conditions. The lanes were loaded with 
commercial BMP-7 (lane 1, control), lysates from HPTC transduced with the BMP-7-
expression vector (lanes 2 and 3), and conditioned medium from such cells (lanes 4 and 
5). An anti-BMP-7 antibody was used, which recognized a broad band at ~ 16 kDa 
(arrowhead). The positions of the 25 kDa and 15 kDa size marker bands were indicated. 
(B) ELISA specific for human BMP-7. The assay was performed with medium from 
normal HPTC cultures treated with 25 ng/ml of commercial BMP-7 (control) or 
conditioned medium obtained from HPTC transduced with the BMP-7-expression vector. 
The conditioned medium was collected at 1, 4 or 8 days after transduction. The 
absorbance at 450 nm was proportional to BMP-7 concentration. The averages ± s.d. of 3 
replicas were shown. There was no significant difference between the control with 
commercial BMP-7 and the conditioned medium collected at day 1 (p > 0.05). 
Conditioned medium collected at day 4 or day 8 contained significantly higher amounts 
of BMP-7 (p < 0.001). Significant differences are indicated by **p < 0.001. 
 
 
4.4.3 Bioactivity of BMP-7 secreted by HPTC  
Next, I tested the bioactivity of BMP-7 produced by HPTC. First, I measured the 
osteoinductive capacity by determining alkaline phosphatase activity of C2C12 
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myoblasts (143). Figure 16 shows that the alkaline phosphatase activity was significantly 
increased when C2C12 cells were treated with 25 ng/ml of commercial BMP-7 (as 
compared to untreated controls; p < 0.05). Alkaline phosphatase activity was further 
enhanced when cells were treated with 100 ng/ml of commercial BMP-7. Similar levels 
of alkaline phosphatase activity were observed when C2C12 cells were treated with 
conditioned medium from transduced HPTC. The viral titer was adjusted so that the 
BMP-7 levels in the conditioned medium one day after transduction were similar to the 
BMP-7 levels in cultures treated with 25 ng/ml or 100 ng/ml of commercial BMP-7 (as 
determined by ELISA). No significant differences (p > 0.05) were observed in the levels 
of alkaline phosphatase activity when C2C12 cells were treated with either 25 ng/ml of 
commercial BMP-7 or conditioned medium from transduced HPTC cultures containing 
similar amounts of secreted BMP-7. Significant differences were also not observed when 
higher concentrations of commercial or secreted BMP-7 were applied (100 ng/ml, p > 
0.05). This suggested that the osteoinductive activities of commercial BMP-7 and BMP-7 
secreted by transduced HPTC were similar.  
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Figure 16: Alkaline phosphatase activity. C2C12 cells were kept in normal cell culture 
medium (control) or in medium supplemented with 25 ng/ml or 100 ng/ml of commercial 
BMP-7. In two experimental series, C2C12 cells were cultivated in conditioned medium 
obtained from BMP-7-secreting HPTC containing 25 ng/ml or 100 ng/ml of HPTC-
produced BMP-7. The amounts of p-nitrophenol produced during a 30-min incubation 
period were determined and normalized to the protein content of the cell samples (y-
axis). The bars show the averages ± s.d. of 3 replicas. Significant differences are 
indicated by *p < 0.05. 
 
 
Next, I determined whether BMP-7 signaling occurred in treated C2C12 cells, which is 
associated with phosphorylation and nuclear translocation of Smad1, Smad5 and Smad8 
(144). Immunostaining was performed with an anti-phosphorylated Smad1/5/8 antibody 
that recognizes the phosphorylated isoforms of all 3 proteins (Fig. 17 A). The 
fluorescence intensity was about 2-fold higher after immunostaining when the C2C12 
cells were kept in conditioned medium obtained from transduced HPTC (as compared to 
controls in non-conditioned cell culture medium; Fig. 17 B; p < 0.001). Similar results 




Figure 17: Immunostaining of phosphorylated Smad1/5/8 in C2C12 cells. (A) The upper 
images show DAPI-stained nuclei. Immunostaining of phosphorylated Smad1/5/8 (p-
Smad1/5/8) is shown on the lower images, which display the same fields of cells as the 
respective upper images. The cells were cultivated in normal cell culture medium 
(control), in medium supplemented with 100 ng/ml of commercial BMP-7 or in 
conditioned medium containing 100 ng/ml of HPTC-produced BMP-7. (B) Relative 
fluorescence intensities (arbitrary units, a.u.) of immunostained phosphorylated 
Smad1/5/8. The relative fluorescence intensities were measured in nuclei of C2C12 cells 
cultivated in normal cell culture medium (control), in medium supplemented with 100 
ng/ml of commercial BMP-7 or in conditioned medium containing 100 ng/ml of HPTC-
produced BMP-7. The bars show the average ± s.d. (8 randomly chosen fields of cells 




As a control, I performed similar experiments with an antibody recognizing the 
phosphorylated isoforms of Smad2 and Smad3. Phosphorylation of these Smads is 
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associated with TGF-β signaling, but not with BMP-7 signaling (144). Treatment of 
C2C12 cells with 100 ng/ml of commercial BMP-7 or with conditioned medium 
containing similar amounts of HPTC-produced BMP-7 did not increase the levels of 
phosphorylated Smad2/3 (Fig. 18), indicating that the signaling was BMP-7 specific. 
 
 
Figure 18: Immunostaining of phosphorylated Smad2/3 and phosphorylated Smad1/5/8 
in C2C12 cells. The upper images show DAPI-stained nuclei. Immunostaining of 
phosphorylated Smad2/3 (p-Smad2/3) and phosphorylated Smad1/5/8 (p-Smad1/5/8) is 
shown on the lower images, which display the same fields of cells as the respective upper 
images. The cells were cultivated in normal cell culture medium (control), in medium 
supplemented with 100 ng/ml of commercial BMP-7 or in conditioned medium 
containing 100 ng/ml of HPTC-produced BMP-7. In all cases, no staining of 
phosphorylated Smad2/3 was observed. Scale bar: 100 µm.  
 
 
I also analyzed expression levels of osteogenic markers in C2C12 cells by qPCR in 
collaboration with my colleague Dr. Karthikeyan Kandasamy. The expression levels of 
the genes for the following osteogenic markers were determined: BGLAP, SPP1, 
RUNX2, SP7, ALPL, DMP1 and PHEX. C2C12 cells were treated with 25 ng/ml or 100 




The expression levels of all of the osteogenic marker genes were significantly increased 
after treatment with BMP-7, and this applied to commercial as well as to HPTC-produced 
BMP-7. In most cases a dose-dependent response was observed and the expression levels 
were higher at the higher concentration of BMP-7. Although both, commercial and 
HPTC-produced BMP-7 were functional and increased the expression of osteognic 
marker genes in a dose-dependent manner, the effects on individual genes were different. 
The largest differences between the effects of commercial and HPTC-produced BMP-7 
were observed in case of ALPL, DMP1 and PHEX.  
 
 
Figure 19: Expression levels of osteogenic genes determined by qPCR. C2C12 cells 
were treated with 25 ng/ml or 100 ng/ml of either commercial or HPTC-produced BMP-
7. The controls were left untreated. The expression levels of the osteogenic markers 
indicated on the x-axis were determined by qPCR. The values obtained for the controls 
were set to 1. The bars show the average ± s.d. (n = 3). Significant differences between 
BMP-7-treated and control samples were indicated by asterisks. (Figure by. Dr. 





4.4.4 Effects of secreted BMP-7 on HPTC  
After determining bioactivity and osteoinductive effects, I investigated whether BMP-7 
secreted by HPTC enhanced HPTC functions, as observed with commercial BMP-7. I 
employed static cultures of HPTC, which were transduced with the same amount of 
lentiviral particles as used for the experiments illustrated in Figure 15 B (25 ng/ml of 
BMP-7 after 1 day). The GGT activity of these cultures was compared to that of HPTC 
cultures treated with 25 ng/ml of commercial BMP-7. Non-transduced HPTC cultures 
incubated with non-BMP-7-supplemented normal culture medium were used as a 
negative control. Both treatment with 25 ng/ml of commercial BMP-7 and transduction 
with the lentiviral expression vector led to a significant increase of GGT activity (as 
compared to non-transduced HPTC incubated with non-supplemented medium, Fig. 20). 
There was no significant difference between the GGT activities of BMP-7-producing 
HPTC and HPTC treated with 25 ng/ml of commercial BMP-7. These results 
demonstrated that HPTC secreting bioactive BMP-7 were generated successfully, and 




Figure 20: GGT activity of BMP-7-expressing HPTC. HPTC were kept in medium 
supplemented with γ-glutamyl-p-nitroanilide and glycyl-glycine. In one experimental 
series, the medium was also supplemented with 25 ng/ml of commercial BMP-7 (control: 
medium not supplemented with BMP-7). Either normal HPTC (control and commercial 
BMP-7) or HPTC transduced with the BMP-7 expression vector were used. The viral titer 
was the same as that used for the experiments related to Figure 5B (25 ng/ml of BMP-7 
secreted after 1 day). The concentrations of p-nitroaniline (nmol) were determined, and 
normalized to the protein content of the cell lysates (mg) and the exposure time to the 
GGT substrates (hr). The bars show the averages ± s.d. of 3 replicas. Significant 
differences are indicated by *p < 0.05 and **p < 0.001. 
 
 
In order to further examine the effects of commercial and HPTC-produced BMP-7 on 
HPTC, I determined the expression levels of 20 marker genes by qPCR (Fig. 21). HPTC 
were treated with 25 ng/ml of either commercial or HPTC-produced BMP-7 or were left 
untreated (control). The marker genes tested included the genes for the epithelial markers 
E-CAD, N-CAD and ZO-1, as well as the genes coding for the brush border enzymes 
CD13 and GGT. The expression of genes coding for the following transporters was 
assessed: SGLT2, PEPT1, PEPT2, GLUT5, OAT1, OAT3, OCT1, OCT N2 and NBC1. 
In addition, the expression levels of the MDR1 and the genes for the Na+/K+ ATPase, 
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AQP1 and the Vit D Hydr were examined. I also determined expression levels of the 
mesenchymal cell marker VIM and α-SMA.  
 
Consistent with the previous data (Fig. 10), the expression levels of α-SMA were not 
altered by treatment with 25 ng/ml BMP-7, which applied also to vimentin. The 
expression levels of 10 epithelial/proximal tubule-specific marker genes were 
significantly increased by treatment with HPTC-produced BMP-7. In 3 cases the 
expression levels were significantly decreased after treatment with HPTC-produced 
BMP-7, whereas in 5 cases no significant changes were observed. Also treatment with 
commercial BMP-7 led to increases in the expression levels of 10 marker genes. 
However, as already observed for the osteogenic genes (Fig. 19), the effects of 
commercial and HPTC-produced BMP-7 on individual genes were different. The largest 
differences were observed in case of the Na+/K+ ATPase, where treatment with 
commercial BMP-7 led to a slight but significant decrease in expression levels, whereas 
treatment with HPTC-produced BMP-7 increased the expression level ~ 8-fold. Overall, 
the results showed that HPTC-produced BMP-7 was bioactive and improved the 





Figure 21: HPTC gene expression levels determined by qPCR. HPTC were treated with 
25 ng/ml of either commercial or HPTC-produced BMP-7. The controls were left 
untreated. The expression levels of the marker genes indicated on the x-axis were 
determined by qPCR. The values obtained for the controls were set to 1. The bars show 
the average ± s.d. (n = 3). Significant differences between BMP-7-treated and control 
samples were indicated by *p < 0.05 and **p < 0.001. 
 
 
In addition to BMP-7, one would expect that other growth factors also contribute to the 
performance of HPTC. In order to learn more about such growth factors, co-culture 
systems would be useful. Therefore, I established and characterized a co-culture system 
consisting of HPTC and endothelial cells. Such systems could then also be used for other 






4.5. Establishment and characterization of a co-culture system 
4.5.1 Effect of endothelial cells on HPTC 
In order to analyze the performance of HPTC when co-cultured with endothelial cells, I 
seeded cells into commercial transwell systems containing polyester membranes. In case 
of mono-cultures, HPTC were seeded into bother upper and lower compartments. In co-
cultures, HPTC were seeded either in the upper or the lower compartment and HUVEC 
were seeded into the remaining component. 
 
 Figure 22 shows phase contrast images of HPTC which had been cultivated for 4 weeks 
in mono- and co-cultures. During this time period, characteristic cell aggregate formation 
associated with disruption and re-organization of the epithelia was observed in mono-
cultures (Fig. 22 A, B). In contrast, these processes did not occur in co-cultures. In case 
of the co-cultures, no cell aggregate formation was observed and the renal epithelium was 
maintained during the whole cultivation period of 4 weeks (Fig. 22 C, D). After 4 weeks 
in co-culture the renal epithelium displayed tight junctions, as revealed by 
immunostaining of the tight junctional protein ZO-1 (Fig. 22 E, F). Tight junctions were 
more extensive and regular in the lower compartment (Fig. 22 E, F). Cells in this 
compartment resided on stiff tissue culture polystyrene (TCPS), whereas they were kept 
on more compliant polyester membranes in the upper compartment. These findings were 
consistent with other results showing that HPTC performed better on TCPS and other 
stiff materials in comparison to more compliant membrane materials (90). Therefore, 
HPTC were kept in the lower compartment in all of the following experiments. 
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Figure 22: HPTC performance in mono- and co-cultures. All panels show HPTC, which 
were cultivated in both compartments of Transwell systems (mono-cultures) or either in 
the upper or the lower compartment (co-cultures). HUVEC were grown in co-cultures in 
the respective non-HPTC-containing compartment. For each condition, three replicates 
were tested and the entire experimental series was performed twice. Cell performance 
was monitored for a time period of 4 weeks. Representative images are shown. (A–D) 
The panels show phase contrast or differential interference contrast (DIC) images. (A, B) 
Cell aggregate formation occurred in mono-cultures, which was associated with re-
arrangements and partial detachment of the cell layer as shown in panel (B). (C, D) The 
epithelium formed by HPTC was maintained during the whole time period of 4 weeks in 
co-cultures. (E, F) ZO-1 immunofluorescence patterns. Tight junction formation was 
improved when HPTC resided in the lower compartment (F). Scale bars: 200 μm (A–D) 
and 50 μm (E, F). 
 
Next, I assessed the influence of HUVEC on HPTC gene expression patterns. HPTC 
were cultivated in mono- or co-cultures and after 4 days the expression of 18 HPTC 
marker genes was assessed by qPCR. The markers tested included the genes for the 
adherent junction proteins, E-CAD, N-CAD, and ZO-1, as well as the genes for the brush 
border enzymes GGT and CD13. Further, the genes for the water channel AQP1, Vit D3 
Hydr and MDR1 were included. Also, the expression of genes encoding the following 
transporters was assessed: OAT1, OAT3, OCT1, OCTN2, GLUT5, Na+/K+ ATPase, 
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NBC1, SGLT2, PEPT1 and PEPT2. I also determined expression of the myofibroblast 
marker α-SMA and the mesenchymal cell marker VIM.  
 
Figure 23 shows that the expression levels of α-SMA and VIM as well as of the epithelial 
junctional proteins remained unchanged in co-cultures (compared to mono-cultures). 
From the 15 remaining HPTC-specific markers 10 were significantly up-regulated, 
whereas the expression levels of the other 5 markers were not significantly changed. 
Overall, this result showed that epithelial and mesenchymal markers remained 
unchanged, whereas the majority of HPTC-specific markers were up-regulated. The 
highest levels of up-regulation were observed in case of genes encoding for transporters 
and channels. Thus, OAT1 was up-regulated ~ 5-fold and OAT3, GLUT5 and AQP1 
were up-regulated ~ 2.5-fold. NBC1 and SGLT2 were up-regulated ~ 2-fold. The levels 





Figure 23: Gene expression levels of HPTC determined by qPCR. The relative 
expression levels of the genes indicated (x-axis) were assessed with HPTC kept for 4 
days in mono-cultures (light grey bars) or co-cultures (dark grey bars). The bars show the 
mean ± standard deviation (s.d., n = 3), and the mean values obtained with mono-cultures 
were set to 1. Significant differences between mono- and co-cultures were indicated by 
asterisks.  
 
In order to confirm the observed up-regulation of gene expression at a functional level I 
determined the activity of the brush border enzyme GGT in mono-and co-cultures of 
HPTC (Fig. 24). HPTC were co-cultivated either with HUVEC or with HRGEC in order 
to exclude that the observed effects of endothelial cells were specific for HUVEC. In 
both co-cultures GGT activity was ~ 1.5-fold higher than in mono-cultures (Fig. 24). This 
is in agreement with the observed up-regulation of the GGT gene as determined by qPCR 
(Fig. 23).  
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Figure 24: GGT activity of HPTC. HPTC were kept for 3 days in mono-cultures or in co-
cultures with either HUVEC or HRGEC. The medium was supplemented with GGT 
substrates and after 1 hour (h) the concentration of the reaction product p-nitroaniline 
(nmol/ml) was determined. The results were normalized to the cell numbers in each 
sample, which were counted after the assay. The bars show the mean ± s.d. of 3 
replicates. Significant differences between mono-and co-cultures were indicated by 
asterisks.  
 
Furthermore, I investigated cell proliferation in mono- and co-cultures. The presence of 
HPTC had no significant influence on the numbers of HUVEC or HRGEC (Fig. 25 A). In 
contrast, significantly higher numbers of HPTC were obtained in co-cultures with 
HUVEC or HRGEC in comparison to mono-cultures (Fig. 25 B) (note that the GGT 
activity (Fig. 24) was normalized to cell numbers and gene expression levels (Fig. 23) 





Figure 25: Cell numbers. The numbers of endothelial cells (A) or HPTC (B) were 
determined by cell counting on day 3 after cell seeding. The bars indicate the numbers of 
the respective cell type per Transwell compartment (mean ± s.d., n = 3). (A) HUVEC or 
HRGEC were cultivated in mono-cultures (light grey bars, the same type of endothelial 
cell in both compartments) or co-cultures with HPTC (dark grey bars). (B) HPTC were 
cultivated in mono-cultures or co-cultures with HUVEC or HRGEC. Significant 
differences between mono-and co-cultures were indicated by asterisks.  
 
 
In summary, endothelial cells influenced different variables of HPTC performance. These 
included cell numbers, gene expression patterns and enzyme activity. In addition, 
endothelial cells inhibited the formation of cell aggregates and the disruption of renal 




4.5.2 The cross-talk between HPTC and HUVEC and soluble factors secreted by HUVEC 
As HPTC and endothelial cells were not in direct contact in our co-culture system it was 
likely that the effects of endothelial cells on HPTC were mediated by secreted soluble 
factors. First, I performed qPCR analyses in order to identify such factors expressed by 
HUVEC. This analysis addressed also the influence of HPTC on their expression. 
 
The qPCR analysis was performed with HUVEC, which had been kept in mono-cultures 
or which had been co-cultivated with HPTC for 4 days (Fig. 26). The expression of the 
genes for the following secreted factors was analyzed: VEGF-A, -B and -C, FGF-2, IGF-
1, HGF, TGF-β1, PDGF-A and PDGF-B. All of these factors are known to be secreted by 
endothelial cells and/or have effects on renal tubular cells. In addition, I analyzed the 
expression levels of the genes for the following receptors: VEGFR-2, FGFR-2 and TGF-
βR1. Figure 11 shows that the levels of VEGFR-2 and TGF-βR1 were similar in mono- 
and co-cultures, whereas the level of FGFR-2 expression was up-regulated (~ 3-fold). 
IGF-1 and PDGF-B expression was similar in mono- and co-cultures. PDGF-A was 
down-regulated. FGF-2 mRNA expression was up-regulated but increased secreted FGF-
2 protein levels could not be detected by ELISA (data not shown). However, there was a 
marked (> 2-fold) up-regulation of VEGF-A, VEGF-B and HGF. These factors are potent 
regulators of endothelial and renal tubular epithelial cells (145-155). 
 
Surprisingly, TGF-β1 showed the largest increase in expression levels, which were ~ 4.5-
fold higher in co-cultures. This result did not appear to be in agreement with the previous 
findings, which showed inhibition of TGF-β1-dependent effects in co-cultures, such as 
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cell aggregate formation and disintegration of epithelia (Fig. 22) and (96, 156). Also, 
improved cell type-specific differentiation (as revealed by marker gene expression, Fig. 
23) and increased HPTC proliferation (Fig. 25) in co-cultures did not seem to be in 
agreement with the observed up-regulation of TGF-β1, as TGF-β1 has known anti-
proliferative effects (157) and induces trans-differentiation of renal epithelial cells (96, 
98). 
 
Therefore, I addressed also the expression levels of the natural TGF-β1 antagonists A2M, 
DCN, FST and FSTL3. FSTL3 was significantly down-regulated (Fig. 26), whereas FST 
and DEC were significantly but only slightly up-regulated (< 2-fold). In contrast, A2M 
was strongly up-regulated. Intriguingly, both A2M as well as TGF-β1 were up-regulated 
in similar ways and in both cases the expression levels were ~ 4.5-fold higher in co-
cultures (Fig. 26). This suggested that A2M was the major antagonist of TGF-β1 in the 
co-culture system used here and that the inhibition of TGF-β1-dependent effects 




Figure 26: Gene expression levels of HUVEC determined by qPCR. The relative 
expression levels of the genes indicated (x-axis) were assessed with HUVEC kept for 4 
days in mono-cultures (light grey bars) or co-cultures (dark grey bars). The bars show the 
mean ± s.d. (n = 3), and the mean values obtained with mono-cultures were set to 1. 
Significant differences between mono- and co-cultures were indicated by asterisks.  
 
 
4.5.3 TGF-β1 and its antagonist A2M regulate the maintenance of renal epithelia 
In order to address this hypothesis I first determined the levels of secreted TGF-β1 and 
A2M in the supernatants of mono- and co-cultures by ELISA. TGF-β1 levels were 
determined separately in the HPTC and HUVEC compartments of co-cultures. The 
results (Fig. 27 A) confirmed that TGF-β1 levels were elevated in co-cultures and that 
HUVEC were the major source of TGF-β1. Further, the results confirmed that TGF-β1 
secretion by HUVEC was significantly increased in the presence of HPTC. In addition, 
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the results confirmed that also A2M secretion by HUVEC was significantly increased in 
the presence of HPTC (Fig. 27 B).  
 
 
Figure 27: Amounts of TGF-β1 and A2M determined by ELISA. HPTC and HUVEC 
were grown in mono-cultures or together in co-cultures as indicated. After 3 days the 
amounts (ng) of (A) TGF-β1 or (B) A2M in the medium were determined and normalized 
to the protein content (mg protein) of the cells residing in the compartment from which 
the medium sample was obtained. As indicated at the bottom of the panels, the medium 
sample was obtained from either the HPTC or the HUVEC compartment when co-
cultures were used. The bars show the mean ± s.d. of 3 replicates. Significant differences 





In order to address the effects of such increased levels of TGF-β1 and A2M at a 
functional level I added similar concentrations of these factors (as found in co-cultures) 
to mono-cultures of HPTC. For these experiments HPTC mono-cultures were kept in 
normal multi-well plates and either TGF-β1 or A2M or a combination of both factors was 
added. Control cells were left untreated. Figure 28 shows the results obtained 2 weeks 
after cell seeding. Variable results were obtained with control cells (Fig. 28 A) and some 
of the wells showed the typical cell aggregates induced by TGF-β1 (note that also HPTC 
secrete some TGF-β1, see Fig. 27 A and (92)). In these wells also cell-depleted areas 
were observed, which were due to re-organization of the epithelium after formation of a 
closed epithelial sheet. In TGF-β1-treated cells these processes were enhanced and all of 
the wells treated with TGF-β1 showed consistently cell aggregates and major re-
arrangements of the epithelium (Fig. 28 B). Also in all of the wells treated with A2M 
large-scale re-arrangements of the epithelium were observed, leading to cell-depleted 
areas. However, cell aggregates were absent (Fig. 28 D). When HPTC were treated with a 
combination of TGF-β1 and A2M (Fig. 28 C) cell aggregates as well as large-scale re-
arrangements were absent and the epithelium was well-preserved.  
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Figure 28: Long-term performance of HPTC in the presence of hr TGF-β1 and/or hr 
A2M. HPTC were cultivated in multi-well plates and assessed after 2 weeks. The 
medium was supplemented during the whole cultivation period with (B) hr TGF-β1 or 
(D) hr A2M or (C) a combination of these factors. (A) Control cells were not 
supplemented with these factors. In each case 5 replicates were assessed and 
representative images are shown. The left-hand panel in (A) and both panels in (B) show 
cell aggregates. The arrowheads point to areas devoid of cells, which arose due to re-
arrangements of the epithelium that occurred after initial formation of a closed cell layer. 
Scale bar: 300 µm. 
 
In summary, a co-culture system consisting of HPTC and HUVEC was successfully 
established and characterized (158). This co-culture system could be useful in the 
development of models for in vitro toxicology and nanotoxicology. Furthermore, the 
factors identified using this co-culture system can be used to improve HPTC performance 




5.1 Characterization of freshly isolated and commercial HPTC 
The results showed that both freshly isolated and commercial HPTC expressed epithelial 
and HPTC-specific markers. Expression of HPTC-specific markers, in particular, the 
transporters, is important for cells used for in vitro nephrotoxicology because de-
differentiation and low expression levels of drug transporters, which renders the cells 
insensitive to drug exposure, is a particular problem in such applications (50). In addition, 
expression of tight junction proteins ZO-1 ensures that HPTC are able to form a non-
leaky monolayer in the BAK. This is important in the BAK so that so that the transport 
functions can be carried out by the HPTC. The thorough characterization of HPTC, 
revealing expression of both HPTC-specific and epithelial markers, suggested that the 
cells could be suitable for applications in nephrotoxicology and BAK development.  
 
Thorough characterization of HPTC is not only important for clarifying the 
differentiation and functional status of the cells but also to ensure the relative purity of 
the cells. Most isolation procedures used so far use mechanical disaggregation, enzymatic 
digestion and sieving techniques for cell separation mostly based on size (130, 159-161). 
These procedures do not use additional steps to separate proximal tubular cells from 
distal tubular cells. One method that has been reported for such separation is through 
immunomagnetic separation of PTC and distal tubular cells using CD13 and THG 
markers respectively (162). However, in our hands such immunomagnetic separation did 
not result in a clear separation of two distinct cell types. In addition, immunomagnetic 
separation resulted in low cell yield of magnetically separated cells and hence limited cell 
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numbers available for research and applications. The low yield obtained after 
immunomagnetic separation is in agreement with other studies which employed 
immunomagnetic separate techniques to isolate endothelial cells (163). Therefore, it is 
not surprising that several labs still use conventional size based separation techniques for 
isolation (130, 159-161). Using these techniques it is important to ensure purity of the 
cell population being used. My results showed that our isolates and commercial cells 
were predominantly of proximal origin. The results suggested that the expression of E-
CAD and THG, which are distal tubule-specific, was due to changes of the expression 
patterns of some markers in in vitro conditions. It has been reported before that proximal 
tubule-derived cells expressed increased levels of E-CAD under in vitro conditions (96, 
164, 165). In addition, it has been reported that distal tubule transdifferentiate to express 
proximal tubule markers (166). Similarly it is also possible that proximal tubule cells can 
express mostly proximal specific but also some distal tubular markers.  
 
The results obtained here also revealed that the expression of several HPTC-specific 
markers and functional performance was better in freshly isolated HPTC compared to 
commercial HPTC. This could be explained, at least in part, by the maintenance of 
isolated HPTC in serum-free conditions. It has been reported that the differential state of 
HPTC and expression of markers can be retained longer in serum free conditions (160, 
167, 168). In addition, commercial cells are obtained at passage 2 from the vendors. 
Isolation of cells in the lab provides much better control over initial culturing conditions. 
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My results showed that, despite the thorough characterization, HPTC performance 
needed further optimization. This is because functional well-differentiated epithelia could 
not be maintained for a prolonged time period. The epithelium was disrupted and cell 
aggregates, high in α-SMA expressing myofibroblasts were observed. The epithelia 
eventually wrapped up to form tubule like structures. Previous studies in our lab 
demonstrated that such tubulogenesis on 2D surfaces was induced by TGF-β1, which was 
probably released in the in vitro system by myofibroblast aggregates (92). It is well 
documented that myofibroblasts release TGF-β1 (169). The central role of TGF-β1 in 
modulating HPTC performance was further confirmed by the results obtained from the 
characterization of co-culture models and growth factors, in particular, TGF-β1 and its 
antagonists, A2M and BMP-7.  This will be discussed in the following sections. 
 
5.2 Characterization of effects of BMP-7 on HPTC and generation of a BMP-7-
producing BAK 
 
The central importance of antagonizing TGF-β1-induced effects, at least in vitro, was 
confirmed by the findings that maintenance of differentiated epithelia formed by HPTC 
could be improved by treatment with the TGF- β1 antagonist, BMP-7. Treatment with 25 
ng/ml of human recombinant BMP-7 also enhanced cell type-specific functions of HPTC, 
and this applied to static cultures as well as to perfusion cultures in bioreactors. 
Furthermore, the expression of various epithelial and proximal tubule-specific 
differentiation markers was improved by treatment with BMP-7. Together, these results 
 108 
suggested that treatment with BMP-7 could help to improve the functional performance 
of HPTC in BAKs.  
 
Treatment of HPTC with BMP-7, which has been shown to enhance epithelial 
differentiation and to counteract epithelial-to-mesenchymal transition of rodent renal 
cells (96, 140) did not reduce the number of myofibroblasts and α-SMA expression at 
any concentration in our experiments. This is in agreement with the recent observation 
that BMP-7 fails to attenuate epithelial-to-mesenchymal transition in human proximal 
tubule cells (99). In fact, the number of myofibroblasts was increased at higher 
concentrations of BMP-7 (and BMP-2), and this result was in agreement with previous 
studies, where pro-fibrogenic activity of BMP-7 was observed (99, 170). Our results 
showed that the pro-fibrogenic effects on HPTC were concentration-dependent, and only 
occurred at relatively high concentrations. 
 
Myofibroblasts play a major role in the processes leading to tubule formation by HPTC 
on substrate surfaces (92). Interestingly, processes associated with tubule formation, such 
as monolayer disruption and rearrangement, as well as the formation of cell aggregates 
and renal tubules, were inhibited at all concentrations of BMP-7, even when high 
numbers of myofibroblasts were present. This suggested that the effects of BMP-7 on the 
maintenance of monolayers were due to uncoupling the appearance of myofibroblasts 
from the processes leading to tubule formation. Myofibroblasts might be tolerable in 




The results showed that either supplementation of the medium with BMP-7 or the 
application of BMP-7-producing HPTC would improve cell performance. Although the 
effects on functional cell performance were similar, the effects of commercial and HPTC-
produced BMP-7 on gene expression levels were gene-specific. This is an interesting but 
an unexpected result. Nevertheless, in both cases the expression levels of the majority of 
osteogenic, epithelial and proximal tubule-specific marker genes were increased. 
Currently the results suggest that one could either take advantage of the controlled release 
of purified growth factor from a device component, or of renal cells expressing BMP-7 in 
order to improve HPTC performance in BAK applications. BMP-7-producing or -
releasing devices could be used to deliver BMP-7 to kidney patients during the BAK 
treatment (Fig 29). The use of BMP-7-producing cells would allow delivery of this 
growth factor to kidney patients at relatively low additional costs.  
 
Figure 29: Schematic of a BMP-7-producing BAK. The patient’s blood (red) first enters 
the hemofiltration unit (left), which contains hollow fiber membranes for ultrafiltration. 
The blood and the ultrafiltrate (yellow) leaving the hemofiltration unit then flow into the 
bioreactor unit (right), which contains hollow fiber membranes with an epithelium of 
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renal cells (green) on the inner surfaces. The cells secrete BMP-7 (violet), which 
becomes enriched in the ultrafiltrate during processing and in the blood flowing on the 
outside of the hollow fiber membranes. The blood enriched in BMP-7 flows back into the 
patient, and the processed ultrafiltrate (orange) is discarded. An enlarged cross-section of 
a hollow fiber membrane from the bioreactor unit is shown in the lower right corner. The 
ultrafiltrate flows in the lumen of the hollow fiber membrane, and the blood flows on the 
outside. The inner surface of the hollow fiber membrane is covered with BMP-7-
secreting renal cells, and BMP-7 becomes enriched in the ultrafiltrate and the blood in the 
bioreactor unit. BMP-7 in the ultrafiltrate would regulate HPTC performance, whereas 
BMP-7 in the bloodstream would be delivered to the patient. 
 
The experiments performed here were designed for the proof of principle and a variety of 
improvements would have to be introduced in order to develop BMP-7-expressing human 
renal cells suitable for clinical applications. For example, although the non-viral system 
did not result in production of sufficient amount of BMP-7, non-viral systems would still 
be most attractive for clinical applications. Otherwise, other viral systems such as 
adenoviral vectors would need to be explored. Nevertheless, the results obtained with the 
viral system suggested that it would be possible to produce sufficient amounts of BMP-7 
with a BAK. In the experiments described in Fig. 15 B, 12.5 ng/day of BMP-7 was 
secreted per cm2 cell-seeded surface area. A BAK with a cell-seeded membrane area of 1 
m2 would produce 125 µg of BMP-7 per day, corresponding to 25 ng/ml per day in an 
individual with a blood volume of 5 l. This is the concentration optimal for the cells in 
the BAK, and well above the physiological levels of BMP-7 (100-300 pg/ml(171)). For 
the experiments shown in Fig 15 B, I diluted the viral supernatant 10-fold in order to 
obtain the optimal concentration. For some experiments (Fig. 16-19), I increased the 
concentration of secreted BMP-7 by 4 folds (i.e. 100 ng/ml after one day), and further 
increases would be possible.  
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Other findings suggested that the amounts of BMP-7 produced by the cells might be in 
the therapeutic range. The lowest dose of BMP-7 that showed significant beneficial 
effects in a murine model of vascular calcification in the context of atherosclerosis and 
chronic renal failure was 10 µg/kg per week (113). With the lower expression rate used 
here, a BAK with a cell-seeded surface area of 1 m2 would produce 12.5 µg/kg per week 
(for a 70-kg individual). In comparison to injections, a BAK would deliver the growth 
factor in a much more continuous mode, especially when prolonged or continuous modes 
of treatment are used.  
 
Given, the beneficial effects of BMP-7 on HPTC and potentially also on the patients’ 
kidneys, it would be useful to carry out animal experiments to further confirm the 
efficacy of a BMP-7-producing BAK. Our lab is currently working on the development 
of a improved BAK suitable for use in animal studies. Both hemofiltration and bioreactor 
units of BAKs applied so far in pre-clinical studies and in clinical trials consisted of 
commercial hemofiltration cartridges. Cartridges containing 
polysulfone/polyvinylpyrrolidone (PSF/PVP) hollow fiber membranes were applied. 
However, as mentioned earlier, such cartridges are not suitable for HPTC performance 
(88). In addition, HPTC performance could not be sufficiently enhanced by applying a 
single ECM coating. Interestingly, recent results from our lab showed that HPTC 
performance was substantially improved after applying a double coating consisting of 
3,4-dihydroxy-l-phenylalanine (DOPA) and collagen IV (88). BAK development using 
application of such coatings is currently under way. Development of a conventional BAK 
containing non-modified HPTC is an essential step in the development of a BMP-7-
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producing BAK. Once such a system is ready, animal studies with a BMP-7-producing 
BAK can be conducted.  
 
5.3 Co-culture of HPTC with endothelial cells  
My results showed that, in addition to treatment with BMP-7, endothelial cells have a 
profound impact on the performance of HPTC in co-cultures by generating a special 
microenvironment. This microenvironment had positive effects on HPTC numbers, cell 
type-specific gene expression, enzyme activity and the maintenance of differentiated 
epithelia during extended time periods. Characteristic for the microenvironment 
generated by the endothelial cells were increased amounts of VEGF, HGF, TGF-β1 and 
its antagonist A2M. HPTC stimulated the production of these factors by endothelial cells, 
which in turn improved the performance of HPTC (Fig. 30).  
 
Figure 30: Summary of the interactions between HPTC and endothelial cells in co-
cultures. The presence of renal epithelial cells (HPTC) stimulated endothelial cells (right 
hand grey arrow), which expressed increased amounts of HGF and VEGF in co-cultures. 
HGF and VEGF have well-characterized effects on both cell types (inner circle of white 
arrows). Endothelial cells also secreted increased amounts of TGF-β1 and its antagonist 
A2M in the presence HPTC (left-hand grey arrows). A2M balanced the effects of TGF-
β1, as illustrated by the Yin Yang symbol, and the long-term maintenance of renal 
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epithelia was improved in the presence of both factors. Co-cultivation with endothelial 
ells also improved HPTC proliferation and differentiation.  
 
 
For instance, HGF and VEGF stimulate growth and survival of renal tubular epithelial 
cells (145-147). In contrast, TGF-β1 can promote epithelial-to-mesenchymal transition 
(EMT) of this cell type (96) and has anti-proliferative effects (157). However, VEGF 
inhibits TGF-β1- induced EMT of renal tubular epithelial cells (172). The results also 
showed that TFG-β1-induced effects were also inhibited by A2M in the 
microenvironment created by endothelial cells. Altogether, the presence of the different 
factors identified here can explain the positive effects of co- cultures on HPTC cell 
numbers, differentiation and improved long-term maintenance of differentiated epithelia.  
 
The factors identified here could potentially also affect endothelial cells. TGF-β1 has 
been shown to have anti-proliferative effects on endothelial cells, which can be 
neutralized by A2M (173). Nevertheless, the results did not show any increased numbers 
of endothelial cells in the presence of HPTC (Fig. 24 A), which stimulated A2M 
expression. However, although not experimentally addressed here, it is well-known that 
HGF (151) and VEGF (150) have profound effects on endothelial cells and stimulate 
survival, proliferation as well as vasculogenesis/angiogenesis. Furthermore, HGF (152, 
153) and VEGF (154, 155) have also been shown to promote tubulogenesis by renal 
epithelial cells either in vitro or ex vivo. Altogether, these results suggest that the renal 
cells stimulated endothelial cells to create a microenvironment that positively affects both 
cell types (Fig. 30) and promotes survival, proliferation, vasculogenesis/angiogenesis or 
tubulogenesis and counteracts uncontrolled de-differentiation and EMT.  
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Generation of such a microenvironment would be important after kidney injury during 
repair and it has indeed been shown that HGF, VEGF and TGF-β1 antagonists have 
beneficial effects in animal models of kidney injury/disease (96, 146, 149, 172). It is 
interesting to note that primary renal proximal tubular cells cultivated in vitro display 
many features of renal tubular cells after kidney injury. These features include enhanced 
proliferation, partial de-differentiation and expression of embryonic markers like PAX-2 
(58). This is not too surprising, given that the primary cells have been obtained by 
disruption of the organ and are kept in an artificial environment. Thus, it is tempting to 
speculate that the HPTC used here generated “injury” signals that stimulated in turn the 
endothelial cells to contribute to the generation of an environment that promoted survival, 
proliferation and regenerative processes of both cell types. It will be highly interesting to 
identify such presumable “injury” signals of renal cells, and co-culture systems will be a 
useful model system for corresponding experimental work. 
 
One interesting question is why endothelial cells up-regulated both, TGF-β1 as well as 
A2M. TGF-β1 plays in vivo important roles in coordinating the response to injury and 
inflammation and TGF-β1 expression is consistently increased in different cell types in 
such situations. However, overshooting TGF-β1 activity has deleterious effects. 
Probably, in the in vivo situation a delicate balance is achieved between TGF-βs secreted 




It is also worth mentioning that A2M binds not only to TGF-β1, but to a large variety of 
growth factors and proteases, which could be important in vivo. Also, binding to other 
factors in the HPTC medium in the absence of increased levels of TGF-β1 might explain 
why the HPTC epithelium was disrupted when the cells were treated with A2M only. 
 
One disadvantage of the model system used here is the fact that peritubular capillary 
endothelial cells could not be used because they were not available. Thus, it cannot be 
excluded that the response of this cell type that is relevant in vivo will be different.  
However, I included at least HRGEC in some experiments and the HPTC response to 
HRGEC and HUVEC was always similar. Thus, the effects did not appear to be specific 
for particular types of endothelial cells. 
 
 Irrespective of the in vivo situation, the results obtained here will be valuable for 
improving HPTC performance under in vitro conditions. In this respect it is important to 
note that the expression levels of OAT1, OAT3 and OCT1 and of various other 
transporters were substantially increased in co-cultures. As mentioned earlier, de-
differentiation and low expression levels of drug transporters renders the cells insensitive 
to drug exposure; this is a particular problem in in vitro nephrotoxicology (50). The 
analysis of the co-culture microenvironment performed here will help to establish 
improved and more defined in vitro culture systems. As discussed before, also in 
bioartificial kidneys it is important to maintain a differentiated HPTC epithelium during 




Overall, establishment and characterization of such a co-culture system allowed us to 
identify another way to improve HPTC performance which would be an alternative to 
treatment with BMP-7. The results will be useful for establishing more defined in vitro 
culture systems. The co-culture system investigated here will also help to study renal 
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α-SMA: α-smooth muscle actin  
ALPL: Alkaline phosphatase, liver, bone, kidney  
AP: Alkaline phosphatase 
AQP1: Aquaporin 1 
ARF: Acute renal failure 
ATCC: American Type Culture Collection  
AVP: Arginine vasopressin 
BAK: Bioartificial kidney 
BGLAP: Bone gamma carboxyglutamate protein  
BMP-2: Bone morphogenetic factor-2 
BMP-7: Bone morphogenetic factor-7 
BSA: Bovine serum albumin 
cAMP : Cyclic adenosine monophosphate 
CVVH : Continuous venovenous hemofiltration 
DAPI: 4’,6’-diamidino-2’-phenylindole 
DCN: Decorin 
DMEM: Dulbecco's Modified Eagle's Medium 
DMP1 : Dentin matrix protein 1 
E-CAD: E-cadherin 
ECM : Extracellular matrix coating 
EMT: Epithelial-to-mesenchymal transition 
ESRD: End stage renal disease 
FBS: Fetal bovine serum  
FGF: Fibroblast growth factor 
FST: Follistatin 
FSTL3: Follistatin-like 3 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase 
GBM: Glomerular basement membrane 
GGT: Gamma glutamyl transpeptidase 
GLUT: Glucose transporter  
HGF: Hepatocyte growth factor 
HPTC: Human primary renal proximal tubular cells 
HUVEC: Human umbilical vein endothelial cells  
HRGEC: Human renal glomerular endothelial cells 
IBMX: 3-isobutyl-1-methylxanthine 
IGF: Insulin-like growth factor 
LAP: Leucine aminopeptidase 
LLC-PK1: Lewis lung cancer-porcine kidney 1 
NUH: National University Hospital  
MDCK: Madin-Darby canine kidney 
MDR1: Multidrug resistance gene 1 
NBC1: Na+HCO3- cotransporter 1 
N-CAD: N-cadherin 
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NUH: National University Hospital  
OAT: Organic anion transporter 
OCT: Organic cation transporter 
PBS: Phosphate-buffered saline 
PDGF: Platelet-derived growth factor 
PEPT: Proton-coupled peptide transporter 
PES: Polyethersulfone 
PHEX: Phosphate-regulating gene with homologies to endopeptidases on the X 
chromosome 
PI: Propidium iodide 
PSF: Polysulfone 
PSF-FC: Polysulfone–Fullcure 
PTC: Proximal tubular cells 
PTH: Parathyroid hormone 
PVP: Polyvinylpyrrolidone 
RAD: Renal tubule assist device 
RUNX2: Runt-related transcription factor 2 
SDS: Sodium dodecyl sulfate 
SGLT: Na+-glucose cotransporter 
SP7: Transcription factor 7 
SSP1: Secreted phosphoprotein 1 
TBS: Tris-buffered saline 
TBS-T: Tris-buffered saline containing 1% Tween-20 
TGF-β1: Transforming growth factor β-1 
THG: Tamm Horsfall glycoprotein 
TRIS: Tris hydroxymethyl aminomethane 
URO10: Uromodulin 10 
VEGF: Vascular endothelial growth factor 
VIM: Vimentin 
Vit D3 Hydr: 25-hydroxyvitamin D3 1-hydroxylase  
ZO-1: Zona occludens-1 
 
 
 
 
 
 
